CLINICAL STUDY PROTOCOL
Study ID: [REMOVED]
Study Title: A Randomized, Open-label, Two-treatment, Two-period, Single-dose, 
Crossover Study to Evaluate the Bioavailability of Teduglutide Administered 
Subcutaneously by [CONTACT_323910]: TAK-633-1001
Protocol Version and Date: 
Amendment 03: 09 Dec 2020
For non-commercial use only
TITLE PAGE
TAKEDA PHARMACEUTICALS
PROTOCOL
A Randomized, Open- label, Two -treatment, Two- period, Single -dose, Crossover Study to 
Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by [CONTACT_323911]: TAK-633-1001 
Compound: Teduglutide
Date: 09Dec2020
Version/Amendment 
Number:Amendment 03
Amendment History : 
Date Amendment Number Amendment Ty pe Region
[ADDRESS_399687] OF APPENDICES ..................................................................................................................6
1. STUDY SUMMARY
...............................................................................................................7
2.STUDY SCHEMATI C................................
...........................................................................12
3.SCHEDUL E OF STUDY PROCEDURES ............................................................................13
4.INTRODUCTION ..................................................................................................................16
4.1 Background ..............................................................................................................16
4.2 Rationale for the Proposed Study .............................................................................17
4.3 Benefit/Risk Profile ..................................................................................................18
5.STUDY OBJECTIVES AND ENDPOINTS ..........................................................................19
5.1 Hypothesis ................................................................................................................19
5.2 Study  Objectives ......................................................................................................19
5.2.1 Study  Primary  Objective ........................................................................................19
5.2.2 Study  Secondary  Objectives ................................
..................................................19
5.3 Endpoints ..................................................................................................................19
5.3.1 Primary  Endpoints .................................................................................................19
5.3.2 Secondary  Endpoints .............................................................................................20
6.STUDY DESIGN AND DESCRI PTION...............................................................................21
6.1 Study  Design ............................................................................................................21
6.2 Dose Escalation ........................................................................................................22
6.3 Rationale for Study Design, Dose, and Endpoints ...................................................22
6.3.1 Rationale of Study  Design ................................
.....................................................22
6.3.2 Rationale for Dose .................................................................................................22
6.3.3 Rationale for Endpoints .........................................................................................22
[IP_ADDRESS] Pharmacokinetic Endpoints ....................................................................22
[IP_ADDRESS] Safety , Tolerabilit y, and Performance Endpoints ..................................23
6.3.4 Future Biomedical Research ..................................................................................23
6.3.5 Critical Procedures Based on Study  Objectives: Timing of Procedures ................ 23
6.4 Study  Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters ................................................................................................................23
6.5 Study  Beginning and End/Completion ................................ ................................ .....23
6.5.1 Definition of Beginning of the Study ................................ ................................ .....23
6.5.2 Definition of End of the Study ................................ ................................ ............... 23
6.5.3 Definition of Study  Completion ................................ ................................ ............. 23
6.5.4 Definition of Study  Discontinuation ................................ ................................ ......24
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 3
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
6.5.5 Criteria for Premature Termination or Suspension of the Study ........................... 24
6.5.6 Criter ia for Premature Termination or Suspension of a Site ..................................24
7.SELECTION AND DI SCONTINUAT ION/WITHDRA WAL  OF SUBJECTS ....................[ADDRESS_399688] Replacement ................................................................................................28
8.CLINICAL STUDY MA TERI AL MANAGEMENT ............................................................29
8.1 Clinical Study  Drug ..................................................................................................29
8.1.1 Clinical Study  Drug Labeling ................................................................................29
8.1.2 Clinical Study  Drug Inventory  and Storage ...........................................................29
8.1.3 Clinical Study  Drug Blinding ................................................................................29
8.1.4 Randomization Code Creation and Storage
...........................................................29
8.1.5 Clinical Study  Blind Maintenance/Unblinding Procedure ....................................30
8.1.6 Accountability  and Destruction of Sponsor -Supplied Drugs
.................................30
9. STUDY PROCEDURES
........................................................................................................31
9.1 Administra tive Procedures .......................................................................................31
9.1.1 Informed Consent Procedure .................................................................................31
[IP_ADDRESS] Assignment of Screening and Allocation Numbers ...............................31
[IP_ADDRESS] Study  Drug Assignment .........................................................................31
9.1.2 Inclusion and Exclusion .........................................................................................31
9.1.3 Medical History /Demography ................................
...............................................31
9.1.4 Concomitant Medications
................................ ................................ ...................... 31
9.2 Clinical Procedures and Assessments ................................ ................................ ......31
9.2.1 Full Phy sical Examination ................................ ................................ ..................... 32
9.2.2 Height and Weight .................................................................................................32
9.2.3 Body Mass Index (BMI) ........................................................................................32
9.2.4 Vital Signs ................................ ................................ ................................ .............. 32
9.2.5 12 -Lead ECG ................................ ................................ ................................ ......... 33
9.2.6 Injection Site Reaction and I njection Site I njury  Assessments .............................33
9.2.7 Study  Drug Administration ....................................................................................33
9.2.8 AE Monitoring .......................................................................................................34
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 4
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
9.2.9 Laboratory  Procedures 
and Assessments ...............................................................34
[IP_ADDRESS] Clinical L aboratory  Tests .......................................................................[ADDRESS_399689] AEs ................................
...............................................................41
10.2 AE Procedures ..........................................................................................................41
10.2.1 Assigning Severit y/Intensity  of AEs ......................................................................41
10.2.2 Assigning Causality  of AEs ...................................................................................42
10.2.3 Start Date ...............................................................................................................42
10.2.4 End Date .................................................................................................................42
10.2.5 Pattern of Adverse Event (Frequency )................................
...................................[ADDRESS_399690] AEs, and 
Abnormal L iver Function Tests .............................................................................43
[IP_ADDRESS] Collection Period ................................
....................................................43
[IP_ADDRESS] Reporting AEs ........................................................................................43
[IP_ADDRESS] Reporting SAEs ......................................................................................44
[IP_ADDRESS] Reporting Special Interest AEs ..............................................................45
[IP_ADDRESS] Close Monitoring and Treatment Discontinuation for Potential 
Drug -Induced Liver Injury (DILI) .........................................................45
10.2.8 Safety  Reporting to Investigators, IRBs or IECs, and Regulatory  Authorities .....46
11.STATI STICAL METH ODS ...................................................................................................47
11.1 Statistical and Analy tical Plans ................................ ................................ ................ 47
11.1.1 Analy sis Sets ................................ ................................ ................................ .......... 47
[IP_ADDRESS] PK Set .....................................................................................................47
[IP_ADDRESS] Safety  Set................................................................................................47
11.1.2 Analy sis of Demography and Other Baseline Characteristics
............................... 47
11.1.3 PK Analy sis................................ ................................ ................................ ........... 47
11.1.4 Pharmacod ynamic Anal ysis................................ ................................ ................... 48
11.1.5 Safety  Anal ysis................................ ................................ ................................ ......48
11.2 Interim Anal ysis and Criteria for Earl y Termination ................................ ............... 48
11.3 Determination of Sample Size ................................ ................................ .................. 49
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 5
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
12.QUALITY CONTROL AND QUALITY ASSURANC E
.....................................................50
12.1 Study -Site Monitoring Visits ...................................................................................50
12.2 Protocol Deviations ..................................................................................................50
12.3 Quality  Assurance Audits and Regulatory  Agency I nspections ..............................50
13.ETHI CAL  ASPECTS OF THE STUDY ................................
................................................51
13.1 IRB and/or IEC Approval ........................................................................................[ADDRESS_399691] Information – Product Quality  Complaint .....................................[ADDRESS_399692] of Abbreviations .............................................................................................57
15.DATA HANDLING AN D RECORDKEEPI [INVESTIGATOR_1645]...................................................................59
15.1 CRFs (Electronic and Paper)
....................................................................................[ADDRESS_399693] Informed Consent ...................................................64
Appendix C Investigator Consent to the Use of Personal Information .............................67
Appendix D Pregnancy  and Contraception ........................................................................68
Appendix E Detailed Description of Amendments to Text ...............................................71
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 7
TAK -633-1001 Protocol Amendment 0 3
Teduglutide 09 Dec 2020
1. STUDY SU MMARY
Nam e of Sponsor:
[COMPANY_005] Development Center Americas, Inc. (TDC Americas)
[ADDRESS_399694]
Lexington, MA 02421Compound:
Teduglutide
Study Identifier (ID): TAK -633-1001 Phase: I
Protocol Title: A Randomized, Open -label, Tw o-treatment, Tw o-period, Single -dose, Crossover Study to 
Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by [CONTACT_323912]:
This is a random ized, open -label, tw o-treatment, two -period, tw o-sequence, single dose, crossover bioavailability 
study in healthy adult subjects. 
Subjects will undergo screening evaluations to determine eligibility within [ADDRESS_399695] dosing. 
Subjects will be enrolled into 1 of 2 cohorts based on their weight ( ≥40.0 kg to ≤75.0 kg [Cohort 1] and >75.0 kg 
to ≤120.0 kg [Cohort 2]). In each cohort, subjects will be admitted to the clinical facility the day prior to each 
dosing and will be confined at least 24 hou rs; subjects w ill be released follow ing com pletion of the 24 -hour 
study procedures in each period. On Day 1 of Period 1, subjects in each cohort will be randomized to 1 of 
2treatment sequences as indicated in Table 1 below . Fixed teduglutide doses (delive red by [CONTACT_323913] -use vials) is 3 mg for subjects in Cohort 1 and 4 mg for subjects in Cohort 2. Each dose will be 
separated by a washout period of 7 days. Blood samples for teduglutide pharmacokinetics (PK) w ill be collected 
predose and for 24 hours following each teduglutide dose. 
Table 1 Treatm ent Scheme for Each Cohort
WeightbandCohort/
Dose 
levelNo. of 
Subjects Sequence*Treatm ent 
Period 1
(Day 1)Washout 
Period
(7 days)Treatm ent 
Period 2
Day 1)
≥40.0 kg -≤75.0 kgCohort 1 
/ 3mgn=16
ABReference
(fixed dose by 
[CONTACT_323914])**→Test
(fixed dose by 
[INVESTIGATOR_311016])** >75.0 kg -≤120.0 kgCohort 2 
/ 4mgn=16
≥40.0 kg -≤75.0 kgCohort 1 
/ 3mgn=[ADDRESS_399696]
(fixed dose by 
[INVESTIGATOR_311016])**→Reference
(fixed dose by 
[CONTACT_323914])* *>75.0 kg -≤120.0 kgCohort 2 
/ 4mgn=16
* To ensure adequate distribution across 3 injection sites (ie, thigh, abdomen, and arm), randomization will be 
stratified by [CONTACT_323915].
**Fixed teduglutide doses (delivered by [CONTACT_323916]- use vials) is 3 mg for subjects in 
Cohort 1 (
≥40.0 kg -≤75.0 kg) and 4 mg for subjects in Cohort 2 (>75.0 kg -≤120.0 kg).
Treatment A: Teduglutide administered by [CONTACT_323917] B: Teduglutide administered by [CONTACT_323918] -emergent adverse events (TEAEs), including injection site 
reaction and injection site injury assessments, clinical laboratory evaluations, physical examinations, and vital 
signs.
All subjects who received at least one dose of study drug (including subjects who terminate the study early) will 
be contact[CONTACT_323919] (CRU) 7 (±2) days after the last study drug administration to 
determine if any adverse event (AE) has occurred since the last study visit.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 8
TAK -633-1001 Protocol Amendment 0 3
Teduglutide 09 Dec 2020
Study Prim aryObjective:
To evaluate the bioavailability of teduglutide following the administration of a single, subcutaneous (SC) fixed 
dose of 3 mg or 4 mg teduglutide (depending upon subjects assignment in one of two cohorts as defined by [CONTACT_149262]) administered via manual injection or via pen injector in healthy subjects.
Study Secondary Objectives:
To evaluate the bioavailability of teduglutide, by  [CONTACT_93403] (ie, thigh, abdomen, and arm) , follow ing the 
administration of a single, SC fixed dose of 3 mg or 4 mg teduglutide (depending upon subjects assignment in 
one of tw o cohorts as defined by [CONTACT_18694]) administered via manual injection or via pen injector in h ealthy 
subjects.
To evaluate other PK parameters of teduglutide, as appropriate, following the administration of a single dose of 
teduglutide administered via manual injection or pen injector in healthy subjects.
To assess the safety and tolerability of SC injections of teduglutide in healthy subjects.
To assess the safety and performance of the pen injector for SC drug administration in healthy subjects.
Study Subject Population: Healthy male and female subjects aged 1 8 –[ADDRESS_399697] in Cohort 1 w ill weigh ≥40.0 kg to ≤75.[ADDRESS_399698] in Cohort 2 will weigh >75.0 kg to ≤120.0 kg at screening and confirmed on Day - 1 of Period 1. 
Plan ned Number of Subjects:
The planned total sample size for this study is 
64randomized subjects. Planned Number of Sites:
1
Dose Levels:
Cohort 1 (body w eight ≥40.0 kg to ≤75.0 kg): 3 mg
Cohort 2 (body w eight >75.0 kg to ≤120.0 kg): 4 mgRoute of Adm inistration:
SC 
Duration of Treatm ent:
Single dosePlanned Study Duration :
Up to 6 w eeks from screening to end of study (follow 
up)
Criteria for Inclusion:
Subjects must fulfill all of the following inclusion criteria to be eligible for participation in the study : 
1. An understanding, ability, and w illingness to fully comply with study procedures and restrictions.
2. Ability to voluntarily provide written, signed, and dated informed consent and assent as applicable to 
participate in the study.
3. Aged [ADDRESS_399699] screening 
visit.
4. Male, or non -pregnant, non -lactating female w ho agrees to comply with any applicable contraceptive 
requirements of the protocol or females of non -childbearing potential, refer to Appendix D .
5. Considered “healthy” by [CONTACT_093]. Healthy status is defined by [CONTACT_323920] a detailed medical and surgical history, a full physical examination including 
vital signs, 12 -lead ECG, hematology, coagulation (as appropriate), serum chemistry, and urinalysis.
6. Body  mass index (BMI) ≥18.0 and ≤32.0 kg/m2at scr eening. Body w eight for a subject in Cohort 1 will 
be ≥40.0 kg to ≤75.[ADDRESS_399700] in Cohort 2 w ill be >75.0 kg to ≤120.[ADDRESS_399701] check -in.
Criteria for Exclusion:
Subjects must not be enrolled in the study if they meet any of the following criteria: 
1. History of any hematological, hepatic, respi[INVESTIGATOR_696], cardiovascular, renal, neurological or psychiatric 
disease, gall bladder removal, or curr ent or recurrent disease that could affect the action, absorption, or 
disposition of the investigational product, or clinical or laboratory assessments.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399702] or procedur es. 
3. Positive PCR (polymerase chain reaction) test for severe acute respi[INVESTIGATOR_6507] -2 
(SARS -CoV- 2), either with the absence or presence of the clinical symptoms of Coronavirus disease 2019 
(COVID- 19).
4. Known or suspected intolerance or hype rsensitivity to teduglutide, closely -related compounds, or any of 
the stated ingredients.
5. Significant illness, as judged by [CONTACT_093], within [ADDRESS_399703] year prior to screening.
7. Donation of blood or blood products (eg, plasma or platelets) within [ADDRESS_399704] dose of teduglutide :
Have used an inves tigational product (if elimination half -life is <6 days, otherwise 5 half-lives).
Have been enrolled in a clinical study (including vaccine studies) that, in the investigator’s (or 
designee’s) opi[INVESTIGATOR_1649], may impact this study.
Have had any substantial changes in eating habits, as assessed by [CONTACT_093] (or designee).
10. Use of dipeptidyl peptidase [ADDRESS_399705] dose of teduglutide.
11. Confirmed systolic blood press ure >140 mmHg or <90 mmHg, and diastolic blood pressure >90 mmHg 
or <40 mmHg at screening.
12. Twelve (12) -lead ECG demonstrating QTcF >[ADDRESS_399706]’s eligibility .
13. Positive screen for drugs of abuse or alcohol at screening and at each check -in.
14. Male subjects who consume more than 21 units of alcohol per w eek or regularly consume more than 
3units per day. Female subjects who consume more than 14 units of alcohol per w eek or regularly 
consume more than 2 units per day. (1 alcohol unit= 150mL of w ine, or 360 mL of beer, or 45 mL o f 45% 
alcohol).
15. Positive HIV, HBsAg, or HCV antibody screen at screening.
16. Use of tobacco in any form (eg, smoking or chewing) or other nicotine -containing products in any form 
(eg,gum, patch) based on subject self -reporting. Ex -users must report that they have stopped using 
tobacco for at least [ADDRESS_399707] dose of teduglutide .
17. Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine 
withdrawal headaches. One caffeine unit is contained in the follow ing items: one 6 oz (180 mL) cup of 
coffee, two 12 oz (360mL) cans of cola, one 12 oz (360 mL) cup of tea, three 1 oz (85 g) chocolate bars.
18. Prior screen failure, randomization, participation, or enrollment in this study, or prior exposure to any 
GLP -[ADDRESS_399708] 
of injection site reaction and injection site injury assessments.
20. Current use of any medication (including over -the-counter, herbal, or homeopathic preparations; with the 
exception of occasional u se of ibuprofen [1.2 g per 24 hour period] or acetaminophen [2 g per 24 hour 
period]). Current use is defined as use within [ADDRESS_399709] dose of teduglutide and throughout the 
study .
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 10
TAK -633-1001 Protocol Amendment 0 3
Teduglutide 09 Dec 2020
Criteria for Evaluation and Analyses:
The primary endpoints of the study are the PK metrics* and will include: 
AUC 0-tlast: Area under the concentration curve from time zero to the time of last measurable concentration 
Cmax: Maximum concentration 
AUC 0-∞: Area under the concentration curve ex trapolated to infinite time
*Beginning on Day 1 of each period, PK parameters will be calculated from reliable teduglutide 
concentration -time profiles using non -compartmental methods where all calculations will be based on actual 
sampling times.
The secondary endpoints will be assessed through evaluation of the following parameters: 
PK metrics* by [CONTACT_93403] (ie, thigh, abdomen, and arm) including:
AUC 0-tlast: Area under the concentration curve from time zero to the time of last measurable co ncentration 
Cmax: Maximum concentration
AUC 0-∞: Area under the concentration curve extrapolated to infinite time
*Beginning on Day 1 of each period, PK parameters will be calculated from reliable teduglutide 
concentration -time profiles using non-compartmental methods where all calculations will be based on actual 
sampling times.
Other s econdary PK parameters w ill include:
tmax: Time of first occurrence of C max
z: Terminal disposition phase rate constant
t1/2: Terminal disposition phase half -life
CL/F: Apparent total body clearance for extravascular administration divided by [CONTACT_323921]/F: Apparent volume of distribution associated w ith the terminal slope following extravascular 
administration divided by [CONTACT_323922]
Occurrence of TEAEs, including injection site reactions and injection site injury assessments.
Routine clinical safety monitoring that includes: vital signs, clinical laboratory test results (hematology, 
serum chemistry, coagulation (as appropr iate), and urinalysis) and physical examinations.
Occurrence of device malfunctions.
The safety endpoint and safety variables will be captured for both test and reference.
A list of potential device malfunctions will be provided to the study site as a reference list for data capture.
Statistical Considerations:
Statistical Methodology for Pharm acokinetic Endpoints
Statistical analysis of PK data will be based on the PK analysis data set. 
All individual concentration data and PK metrics will be listed for each subject and treatment together with 
summary statistics such as geometric mean, median, arithmetic mean, standard deviation (SD), coefficient of 
variation, geometric coefficient of variation, and minimum and maximum grouped by [CONTACT_323923]. The 
time until first occurrence of C maxis reached (t max) will be also listed for each subject and treatment and 
summarized by [CONTACT_7864], minimum and maximum grouped by [CONTACT_323923]. The number of time points 
of the terminal log -linear phase used to estimate the terminal rate constant ( z) and the residual area w ill be also 
provided for each subject and treatment. 
Individual concentration -time curves will be presented in linear/linear and log/linear scale. Figures showing the 
mean (with ±SD as error bars) as w ell as the median (with 25thto 75thquantiles as error bars) concentration time 
profiles grouped by [CONTACT_323923] w ill be also presented in linear/linear and log/linear scale.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 11
TAK -633-1001 Protocol Amendment 0 3
Teduglutide 09 Dec 2020
ThePKendpoints will also be analyzed by [CONTACT_93403] (ie,thigh, abdomen, and arm) .
PK metrics AUC 0-tlast, AUC 0-∞, and C maxwill be analyzed using an analysis of variance (ANOVA) model for 
each cohort separately. 
PK metrics will be transformed prior to analysis using a logarithmic transformation. The difference in means and 
thecorresponding tw o-sided 90% confidence interval (CI) on the log -transformed scale will be obtained from 
that model. The difference in means and the corresponding CI will be back -transformed to obtain the ratio of 
geometric means and the corresponding tw o-sided 90% CI for the ratio on the original scale. The terms used in 
the ANOVA model will be sequence, subject w ithin sequence, period, and treatment. According to EMA 
guideline (CPMP/EWP/QWP/1401/98 Rev. 1/ Corr) (EMA 2010), subjects w ho w ill not provide evaluable data 
for both periods will be not included and fixed effects will be used for all terms.
To assess bioavailability between test and reference, the 90% CI for the ratio of geometric means for PK metrics, 
AUC 0-tlast, AUC 0-∞, and Cmaxwill be derived and compared (and w ould be contained within the acceptance 
interval of 80.00 to 125.00% if bioequivalent).
Statistical Methodology for Safety Endpoints:
Statistical analysis of safety data w ill be based on the safety analysis data set.
Safety data will be listed by [CONTACT_323924]. 
Continuous variables will be summarized by [CONTACT_19462], mean, SD, median, minimum, and maximum. 
Categorical variables will be summarized by [CONTACT_323925].
TEAEs will be analyzed using the number and percentage of subjects reporting events, as well as the number of 
events, by [CONTACT_6657], severity, and causal relationship to the study treatment and 
device. Among TEAEs, injection site reactions and injection site injuries will be analyzed using the number and 
percentage of subjects reporting events, by [CONTACT_11702], severity, and causal relationship to study treatment 
and device . Laboratory tests, vital signs, physical examinations, and corresponding changes from baseline will be 
summarized by [CONTACT_323926] -missing assessment on or before Day [ADDRESS_399710] and summarized by [CONTACT_323927].
Sample Size Justification:
The overall pow er for the endpoints ( AUC 0-tlast, AUC 0-∞, and Cmax) with a total sample size of 64 subjects w ill be 
92.6% power based on a 5% type 1 error and a Coefficient of Variation of 21%, assuming a true ratio of 
test/reference of 1.0 in their relative bio -availabilities based on the acceptance interval of 80.00 to 125.00%. The 
sample size of 28 subjects w ithin each cohor t (14 each sequence) w as accounted for approximately 10% 
potential drop -outs and/or non -reliable concentration time -profiles to yield 32 subjects per cohort (16 subjects 
per sequence within each cohort). This sample size was calculated w ith SAS v9.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 12
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
2. STUDY SCHEMATIC 
  
ScreeningTreatm ent 
Period 1
(Day 1)Treatm ent 
Period 2
(Day 1) Washout
Screening Period = Day -[ADDRESS_399711] DosingDay -1 – Admission to CRU 
Day prior to Period 1 DosingReference
TestRelease from CRU ([ADDRESS_399712] Period 1 Dose)Day -1 – Admission to CRU 
Day prior to Period 2 DosingRelease from CRU ([ADDRESS_399713]
Reference
7 days between teduglutide dose in Period 1 and Period 27 (± 2) days after the last study drug administration
FU=Follow  up
Fixed teduglutide dose (delivered by [INVESTIGATOR_311016] [test] or from approved single -use vials [reference]) is 3 m g for 
subjects in Cohort 1 (≥40.0 kg to ≤75.0 kg) and 4mg for subjects in Cohort 2 ( >75.0 kg to ≤120.0 kg)Cohort 1 (3 m g Teduglutide) and Cohort 2 (4 m g Teduglutide)
2-Period Crossover
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 13
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
3.
SCHEDULE OF STUDY PR OCEDURES 
Study Proceduresa
ScreeningbStudy Days in Each Period (Period 1 and Period 2)c Washout
(7 days)c ETeFUf
Hours → C-IdPredose 0 0.5 1 2 3 4 5 6 8 10 12 14 16 24
Administrative Procedures
Visit X
Informed Consent X
Inclusion/Exclusion Criteria X Xg
Demography and Medical/Medication 
HistoryX
Safety Evaluations 
Full Physical ExaminationhX XmX
Abbreviated Physical ExaminationhX Xn
Height X
Weight X X
12-Lead ECGiX
Vital Signs (heart rate, blood pressure, 
respi[INVESTIGATOR_697], and temperature)i X XjX X X
Hematology, Serum Chemistryk, 
Coagulation (as appropriate), and 
Urinalysis X X X X
Serum Pregnancy Test (females only) X XlXmX
Serum FSH (postmenopausal females 
only)X
Urine Drug and Alcohol Screen X X
HIV, HBsAg, and HCV Antibodies X
AE Monitoring X
Concomitant Medication Monitoring X
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 14
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
Study Proceduresa
ScreeningbStudy Days in Each Period (Period 1 and Period 2)c Washout
(7 days)c ETeFUf
Hours → C-IdPredose 0 0.5 1 2 3 4 5 6 8 10 12 14 16 24
Study Drug Administration / PK
Teduglutide Administrationo X
Blood for T eduglutide PK X X X X X X X X X X X X X X
Other Procedures
Randomization Xg
Injection Site Reaction and Injection 
Site Injury Assessment X XpX X X X X X X X
Device Malfunction Assessment Xq
Confinement in the CRUr X
AE=Adverse events; C-I=Check -in; CRU=Clinical research unit; ECG=Electrocardiogram; ET=Early termination; FSH=Follicle -stimulating hormone; FU=Follow -up; 
HBsAg=Hepatitis B surface antigen; HCV=Hepatitis C virus; HIV=Human immunodeficiency virus; PK=Pharmacokinetics
a For details on Procedures, refer to Section 9.
b Within [ADDRESS_399714] teduglutide administration.
c There will be a washout period of 7 days between the teduglutide dose in Period 1 and Period 2.
d Subjects will be admitted to the CRU on Day -1 of each period at the time indicated by [CONTACT_47365]. Subjects may be admitted earlier for Coronavirus Disease 2019 (COVID -19) 
testing not related to study protocol as per CRU requirements. If the CRU decides to confine the subjects throughout the st udy (ie, washout period[s]), some safety events at 
check -in (eg, clinical laboratory test, urine drug and alcohol screen, pregnancy test, and vital signs) may not be performed at the investigator’s discretion.
e To be performed prior to ET from the study. 
f A ll subjects who received at least one dose of study drug (including subjects who terminate the study early) will be contact[CONTACT_323928] 7 (±2) days after the last study drug 
administration to determine if any AE has occurred since the last study visit.
g Will be performed in Period 1 only. Subjects will be assigned to a cohort based on their weight and will receive the study trea tments according to the randomization scheme. In 
each cohort, subjects will be randomized to 1 of 2 sequences and administered a si ngle dose of teduglutide on Day 1 of each period per the randomization sequences, either AB or 
BA (as defined in the study protocol). To ensure adequate distribution across 3 injection sites (ie, thigh, abdomen, and arm) , randomization will also be stratif ied by [CONTACT_323929].
h Full physical examinations will be performed at screening and prior to discharge at Period 2. Abbreviated physical examinatio ns will be performed at check -in for each period 
and prior to release at Period 1 (See Se ction 9.2.1 ). Symptom -driven physical examinations may be performed at other times, if deemed necessary by [CONTACT_1719].
i ECGs and vital signs will be performed after [ADDRESS_399715] in the supi[INVESTIGATOR_2547].
j To be performed within 24 hours prior to dosing in each period.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 15
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
Study Proceduresa
ScreeningbStudy Days in Each Period (Period 1 and Period 2)c Washout
(7 days)c ETeFUf
Hours → C-IdPredose [ADDRESS_399716] will receive teduglutide on 2 occasions, (ie, on Day 1 of each period, either by [CONTACT_323930] [vial and syr inge) or pen injector in a crossover fashion).
p The injection sites will be assessed for injection site reactions a nd injection site injuries immediately postdose (ie, ≤2 minutes). 
q To be performed for the test product (pen injector) during preparation, immediately prior, and post teduglutide administratio n.
r Subjects will be confined in each period for at least [ADDRESS_399717] 
may be required to remain at the CRU for longer at the discretion of the investigator or designee.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 16
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
4. INTRODUCTION
4.1 Background
Teduglutide (ALX -0600, [gly 2]-hGLP -2) is a novel, recombinant analog of naturally  occurring 
human glucagon like peptid
e-2 (GLP -2), formulated for the treatment of short bowel sy ndrome 
(SBS). Teduglutide accelerates intestinal adaptation after bowel resection and enhances selective 
barrier function in the small intestine ( Jeppesen et al., 2005 ; Jeppesen, 2007 ; Mardini and 
de Villiers, 2008). Data from previous investigations have shown functional changes in cry pts 
and villi in humans following administration of teduglutide. The European Commission granted 
a centralized marketing authorization valid th roughout the European Union (EU) for teduglutide 
(REVESTIVE®). A New Drug Application for teduglutide (GATTEX®) was approved by  [CONTACT_33104] (US) Food and Drug Administration (FDA) and teduglutide was recentl y approved 
for the treatment of patients ag ed ≥1 year with SBS in the EU, the US, and Canada. Teduglutide 
is currentl y approved in >30 countries.
Efficacy 
In pi[INVESTIGATOR_323900], the evidence demonstrates that teduglutide at a daily  
dose of 0.05 mg/kg administered SC is effecti ve in treating parenteral support (PS) -dependent 
adults with SBS by [CONTACT_1541] a clinically
 meaningful reduction in weekly  PS volume. The 
results are reproducible and generalizable across a broad population of adult SBS subjects. 
Results of the long -term ex tension studies demonstrate the reproducibility as well as the 
durability  of the beneficial effects of teduglutide 0.05 mg/kg/day , without evidence for the 
development of tolerance during up to 30 months of treatment. In another extension study  of 
subjects treated for an additional 24 months after receiving 24 weeks of teduglutide in the core 
study , the response to long -term treatment with teduglutide 0.05 mg/kg/day  was maintained in 
subjects initially  treated with teduglutide in the core study , with furthe r reductions in PS volume 
relative to baseline and fewer day s per week of PS support. The responses to treatment with 
teduglutide were accompanied b y an increase in mean plasma citrulline, indicating increased 
enterocy te mass.
Pharmacokinetics
The PK of teduglutide has been investigated following single SC administration at fixed doses of 
2.5 to 10 mg (Study  1621/13). Following SC administration, the plasma C maxof teduglutide 
occurred at approximately  3 to 4 hours postdose with the exposure (C maxand AUC ) increasing 
approximately  in a dose proportional manner. Following a o ne-time PK sampling conducted at 
the beginning of the initial 24- week teduglutide treatment period ( 0.05 mg/kg SC once daily )in 
Study  TED -C14-004, a maximum mean plasma concentration o f 49.7 ng/mL  was achieved at 
2.64±1.02 hours (t max) and the mean AUC 0-
tand AUC 0-infvalues were 201±51.6 and 
204±51.1 ng•hr/mL, respectivel y. Teduglutide was absorbed and rapi[INVESTIGATOR_2478] y eliminated from plasma 
with mean t½ of 1.21±0.65 hours. The mean plasma clea rance was 14.5±4.09 L/hr and the mean 
body  weight normalized plasma clearance was 0.0259±0.0672 L/hr/kg. Teduglutide total 
exposure after SC administration was shown to be similar, irrespective of the site of 
administration (abdomen, arm, or thigh) (Study  CL0600- 015). 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 17
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
Safety
The safet y of teduglutide has been examined in 9 studies in healthy  subjects. Teduglutide was 
well-tolerated in these studies. The AEs experienced b y the healthy subjects were consistent with 
those experienced in clinical studies of 
SBS and Crohn’s subjects. There were no 
treatment -related SAEs or deaths reported in these studies. There were no clinically  significant 
changes or results noted from clinical laboratory  evaluations, vital sign measurements, ECG 
readings, or ph ysical examination findings. The most common adverse reactions across all 
studies were abdominal pain, injection site reactions, nausea, headaches, abdominal distension, 
and upper respi[INVESTIGATOR_2826]. 
For further information on teduglutide, refer to the curre nt edition of the Investigator’s Brochure 
(IB).
4.2 Rationale for the Proposed Study
A new pen injector is being developed to simplify  the dose preparation and administration of 
teduglutide. Extensive in vitro device verification work will be performed to eval uate the safet y 
and performance of the device. Device performance will evaluate dose accuracy  and consistency  
of dose delivery  using the pen injector in accordance with The International Organization for 
Standardization: [ZIP_CODE]- 1 standards.
This clinical bioavailability  study  is intended to support the bridging between the commercially  
available vial drug primary  container administered via a sy ringe injection (eg, s yringe and 
approved vials) versus the pen injector.
The purpose of this stud y is to evaluate t he bioavailability  of teduglutide administered as a single 
SC fixed dose (depending upon subject weightband assignment) delivered by  a syringe injection 
and the same fixed dose delivered b y the pen injector in health y subjects.
Throughout the clinical deve
lopment program for SBS, teduglutide has been administered dail y 
by [CONTACT_323931], thigh, or abdomen based on individual subject body  weight.
Currently  the approved preparation and injection material includes off -the-shelf sy ringes (for 
manual injec tion) and needles. Therefore, a clinical bioavailability  study  is necessary  to evaluate 
the exposure of fixed doses of teduglutide when administered by  [CONTACT_10177] (test) relative to 
the currently  approved configuration by  [CONTACT_323930] (reference ). Conducting such a study  in 
healthy  population is justifiable to avoid confounding factors from patients with SBS. 
Data from this study will be evaluated based on EMA Guideline CPMP/EWP/QWP/1401/98 
Rev. 1/ Corr. (EMA 2010) and the FDA’s Guidance for Industry : Bioavailability  and 
Bioequivalence Studies Submitted in NDAs or INDs — General Considerations (FDA 2019).
The washout period between doses is considered sufficient to prevent carryover effects of the 
preceding treatment.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 18
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
4.3 Benefit/Risk Profile
The risks associated with dosing teduglutide are anticipated to be similar to those previously  
documented in the IB and product label for teduglutide and are not anticipated to induce an y 
potential risk to healthy  subjects participating in this study  (current IB edition, GATTEX®, 
Prescribing Information, 2018).
The doses provided in the study  are based on the dosing recommendations of the product label 
ie,approximately  5 mg for a 100 kg person ,as the recommended dail y dose of teduglutide is 
0.05 mg/kg bod y we ight administered by  [CONTACT_323932]  (GATTEX®, Prescribing 
Information, 2018).
The inclusion and exclusion criteria, screening, and safet y monitoring practices employed b y this 
protocol (ie, vital signs, clinical laboratory  tests, AE questioning, i njection site reaction and 
injection site injury  assessments, and phy sical examinations) are adequate 
to protect the subject’s 
safet y and should detect all TEAEs.
There will be no direct health benefit for study  participants from receipt of study  drug. An 
indirect health benefit to the subjects enrolled in this study  is the free medical tests received at 
screening and during the study .
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 19
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
5.
STUDY OBJECTIVES AND ENDPOINTS
5.1 Hypothesis
Hypothesis testing is not relevant for a bioavailability  study .
5.2 Study Objectives
5.2.1 Study Primary Objective
To evaluate the bioavailability  of teduglutide following the administration of a single, SC fixed 
dose of 3 mg or 4 mg teduglutide (depending upon subjects assignment in one of two cohorts as 
defined b y bod y weight) administered via manual injection or via pen injector in healthy  
subjects.
5.2.2 Study Secondary Objectives
To evaluate the bioavailability  of teduglutide, by  [CONTACT_93403] (ie, thigh, abdomen, and arm) , 
following the administration of a single, SC fixed dose of 3 mg or 4 mg t eduglutide (depending 
upon subjects assignment in one of two cohorts as defined b y bod y weight) administered via 
manual injection or via pen injector in health y subjects.
To evaluate other PK parameters of teduglutide, as appropriate, following the adminis tration of a 
single dose of teduglutide administered via manual injection or pen injector in healthy  subjects.
To assess the safet y and tolerability of SC injections of teduglutide in healthy subjects.
To assess the safet y and performance of the pen inject or for SC drug administration in healthy  
subjects.
5.3 Endpoints
5.3.1 Primary Endpoints
The primary  endpoints of the study  are the PK metrics* and will include: 
AUC 0-tlast: Area under the concentration curve from time zero to the time of last measurable 
concentration 
Cmax: Maximum concentration
AUC 0-∞: Area under the concentration curve extrapolated to infinite time
*Beginning on Day  1 of each period, PK parameters will be calculated from reliable teduglutide 
concentration -time profiles using non
-compartmental methods where all calculations will be 
based on actual sampling times.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 20
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
5.3.2 Secondary Endpoints 
The secondary  endpoints will be assessed through evaluation of the followi ng parameters: 
PK metrics* by  [CONTACT_93403] (ie, thigh, abdomen, and arm) including:
AUC [ADDRESS_399718]: Area under the concentration curve from time zero to the time of last measurable 
concentration 
Cmax: Maximum concentration
AUC 0-∞: Area under the concentrat ion curve extrapolated to infinite time
*Beginning on Day  1 of each period, PK parameters will be calculated from reliable teduglutide 
concentration -time profiles using non
-compartmental methods where all calculations will be 
based on actual sampling times.
Other secondary  PK parameters will include:
tmax: Time of first occurrence of C max
z: Terminal disposition phase rate constant
t1/2: Terminal disposition phase half -life
CL/F: Apparent total body  clearance for extravascular administration divided by  [CONTACT_323933]/F: Apparent volume of distribution associated with the terminal slope following 
extravascular administration divided by  [CONTACT_323934]
Occurrence of TEAEs, including injection site reactions and injection site injury  assessments.
Routine clinical safet y monitoring that includes: vital signs, clinical laboratory  test results 
(hematology , serum chemistry , coagulation (as appropriate), and urinal ysis) and phy sical 
examinations.
Occurrence of device malfunction s.
The safet y endpoint and safet y variables will be captured for both test and reference.
A list of potential device malfunctions will be provided to the study  site as a reference list for 
data capture.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399719] 
dosing. 
Subjects wi ll be enrolled into 1 of 2 cohorts based on their weight ( ≥40.0 kg to ≤75.0 kg 
[Cohort 1] and >75.0 kg to ≤120.0 kg [Cohort 2]). In each cohort, subjects will be admitted to the 
clinical facilit y the day prior to each dosing and will be confined at least 2 4 hours; subjects will 
be released following completion of the 24 -hour study  procedures in each period. On Day 1 of 
Period 1, subjects in each cohort will be randomized to 1 of 2 treatment sequences as indicated in 
Table 2below. Fixed teduglutide doses (delivered by [CONTACT_323916] -use 
vials) is 3 mg for subjects in Cohort 1 and 4 mg for subjects in Cohort 2. Each dose will be 
separated b y a washout period of 7 day s. Blood samples for teduglutide PK will be collected 
predose and for 24 hours following each teduglutide dose. 
Table 2 Treatment Scheme for Each Cohort
WeightbandCohort/
Dose levelNo. of 
Subjects Sequence*Treatm ent 
Period 1
(Day 1)Washout 
Period
(7 days)Treatm ent 
Period 2
Day 1)
≥40.0 kg -≤75.0 kgCohort 1 / 
3mgn=16
ABReference
(fixed dose by 
[CONTACT_323914])**→Test
(fixed dose by 
[INVESTIGATOR_311016])** >75.0 kg -≤120.0 kgCohort 2 / 
4mgn=16
≥40.0 kg -≤75.0 kgCohort 1 / 
3mgn=[ADDRESS_399720]
(fixed dose by 
[CONTACT_323935])**→Reference
(fixed dose by 
[CONTACT_323914])**>75.0 kg -≤120.0 kgCohort 2 / 
4mgn=16
*To ensure adequate distribution across 3 injection sites (ie, thigh, abdomen, and arm), randomization will be 
stratified by [CONTACT_323915].
**Fixed teduglutide doses (delivered by [CONTACT_323916] -use vials) is 3 mg for subjects in Cohort 1 
(
≥40.0 kg -≤75.0 kg) and 4mg for subjects in Cohort 2 (>75.0 kg -≤120.0 kg).
Treatment A: Teduglutide administered by [CONTACT_323917] B: Teduglutide administered by [CONTACT_323936], including injection site reaction and injection 
site injury  assessments, clinical laborat ory evaluations, phy sical examinations, and vital signs.
All subjects who received at least one dose of study  drug (including subjects who terminate the 
study  early) will be contact[INVESTIGATOR_530] b y the CRU 7 (±2) days after the last study  drug administration to 
deter mine if an y AE has occurred since the last study  visit.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399721] acts as their 
own control. To ensure adequate distribution across 3 injection sites (ie, thigh, abdomen, and 
arm), randomization will also be stratified b y injection site within each cohort.
The washout period between doses is considered sufficient to prevent carryover effects of th e 
preceding treatment.
6.3.2 Rationale for Dose 
Teduglutide is indicated for the treatment of adult and pediatric patients with SBS. The European
Commission granted a centralized marketing authorization valid throughout the EU for 
teduglutide (REVESTIVE®). A Ne w Drug Application for teduglutide (GATTEX®) was 
approved b y the US FDA and teduglutide was recently approved for the treatment of patients 
aged ≥1year with SBS in the EU, the US, and Canada. Teduglutide is currently approved in 
>30countries. Teduglutide 0.05 mg/kg/day  has demonstrated a favorable benefit- risk profile in 
clinical studies in adults with SBS.
To simplify  dosing procedures and reduce dosing errors, a dosing regimen based on weightbands 
was explored by [CONTACT_323937] (i ncluding PK and exposure -response 
analyses) based on the available clinical data. The 2 weightbands proposed are (based on 
modeling) ≥40.0 kg to ≤75.0 kg (Cohort 1) and >75.0 kg to ≤120.0 kg (Cohort 2). Any  subject in 
the weightband of ≥40.0 kg to ≤75 kg ( Cohort 1) will receive a fixed 3 mg single dose and the 
weightband of >75.0 kg to ≤120.0 kg (Cohort 2) will receive a fixed 4 mg single dose. The 
proposed fixed doses are expected to deliver comparable exposures to those when using the 
weight -based dose of 0.05 mg/kg once daily .
6.3.3 Rationale for Endpoints
[IP_ADDRESS] Pharmacokinetic Endpoints
The PK endpoints are standard for this bioavailability  study .
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 23
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
[IP_ADDRESS] Safety, Tolerability, and Performance Endpoints 
The key  safet y and tolerability  endpoints are t ypi[INVESTIGATOR_323901] [ADDRESS_399722] using the device.
6.3.4 Future Biomedical Research 
Not applicable.
6.3.5 Critical Procedures Based on Study Objectives: Timing of Procedures 
For this study , the critical component is the blood collection for plasma con centrations of 
teduglutide , and is to be collected as close to the scheduled times defined in this protocol as 
possible . 
6.4
Study Design/Dosing/Procedures Modifications Permitted Within Protocol 
Parameters
The dose and administration of the study  drug to any subject may  not be modified. If necessary , 
a subject may  be discontinued for the reasons described in Section 7.5. Discontinued subjects 
may be replaced at the discretion of the Sponsor and the investigator.
6.5 Study Beginning and End/Completion
6.5.1 Definition of Beginning of the Study
The beginning of the study  will be defined as the beginning of the screening (ie, signing of the 
ICF) of the first subject.
6.5.[ADDRESS_399723] scheduled stud y procedure (ie, the follow -up 
contact [INVESTIGATOR_106006] 7 [±2 days] for all subjects including those who received at least one dose of 
study  drug and withdrawn earl y) as outlined in the Schedule of Study Procedures (Section 3).
6.5.[ADDRESS_399724] welfare.
The Sponsor reserves the right to suspend or terminate the study  at any  time .
6.5.5 Criteria for Premature Termination or Suspension of the Study
The study  will be completed as planned unless one or more of the following criteria are satisfied 
that require temporary  suspension or earl y termination of the study :
New information or other evaluation regarding the safet y or efficacy of the study  medication 
that indicates a change in the known risk/benefit profile for the product, such that the risk is 
no longer acceptable for subjects participating in the study .
Significant violation of Good Clinical Practice (GCP) that compromises the ability  to achieve 
the primary  study  objectives or compromises subject safety .
6.5.6 Criteria for Premature Termination or Suspension of a Site
There is no predetermined criteria for termination of suspension of a site. 
Termination or suspension of a site may  occur at any  time at the discretion of the Sponsor .
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 25
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
7. SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECT S
7.[ADDRESS_399725] fulfill all of the following inclusion criteria to be eligible for participation in the 
study :
1. An understanding, ability, and willingness to full y comply  with study  procedures and 
restrictions.
2. Ability  to voluntaril y pro vide written, signed, and dated informed consent and assent as 
applicable to participate in the study .
3. Aged [ADDRESS_399726] screening visit.
4. Male, or non
-pregnant, non -lactating female who agrees to comply  with any  applicable 
contraceptive requirements of the protocol or females of non- childbearing potential, refer 
to Appendix D .
5. Considered “healthy ” by [CONTACT_093]. Healthy  status is defined by  [CONTACT_10175] y active or chronic disease following a detailed medical and surg ical history , a full 
physical examination including vital signs, 12- lead ECG, hematology , coagulation (as 
appropriate), serum chemistry , and urinal ysis.
6. BMI ≥18.0 and ≤32.0 kg/m2at screening. Bod y weight for a subject in Cohort 1 will be 
≥40.0 kg to ≤75.[ADDRESS_399727] in Cohort 2 will be >75.0 kg to 
≤120.[ADDRESS_399728] not be enrolled in the study  if they meet an y of the following criteria:
1. History  of any  hematological, hepatic, respi[INVESTIGATOR_696], cardiovascular, renal, neurological or 
psychiatric disease, gall bladder removal, or current or recurrent disease that could affect 
the action, absorption, or disposit ion of the investigational product, or clinical or laboratory  
assessments.
2. Current or relevant history  of physical or ps ychiatric illness, any medical disorder that may 
require treatment or make the subject unlikel y to fully  complete the stud y, or an y cond ition 
that presents undue risk from the investigational product or procedures.
3. Positive PCR test for SARS -CoV -2, either with the absence or presence of the clinical 
symptoms of COVID-19.
4. Known or suspected intolerance or h ypersensitivity to teduglutide, cl osely-related 
compounds, or an y of the stated ingredients.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399729] y ear prior to screening.
7. Donation of blood or blood products (eg, plasma or platelets) within [ADDRESS_399730] dose of teduglutide :
Have used an investigational product (if elimination half -life is <6 day s, otherwise 
5half-lives).
Have been enrolled in a clinical study  (including vaccine studies) that, in the 
investigator’s (or designee’s) opi[INVESTIGATOR_1649], may  impact this study .
Have had an y substantial changes in eating habits, as ass essed b y the investigator 
(or designee).
10. Use of dipeptid yl peptidase [ADDRESS_399731] dose of teduglutide.
11. Confirmed sy stolic blood pressure >140 mmHg or <90 mmHg, and diastolic blood 
pressure >90 mmHg or <40 mmHg at screening.
12. Twelve (12)-lead ECG demonstrating QTcF > [ADDRESS_399732]’s eligibility .
13. Positive screen for drugs of abuse or alcohol at screening and at each check -in.
14. Male subjects who consume more than 21 units of alcohol per week or regularly  consume 
more than 3 units per day. Female subjects who consume more than 14 units of alcohol per 
week or regularl y consume more than 2 units per day . (1alcohol unit=150 mL of wine, or 
360mL of beer, or 45 mL of 45% alcohol).
15. Positive HI V, HBsAg, or HCV antibody  screen at screening.
16. Use of tobacco in an yform (eg, smoking or chewing) or other nicotine -containing products 
in any  form (eg, gum, patch) based on subject self- reporting. Ex -users must report that they  
have stopped using tobacco for at least [ADDRESS_399733] dose of 
teduglut ide.
17. Routine consumption of more than 2 units of caffeine per day  or subjects who experience 
caffeine withdrawal headaches. One caffeine unit is contained in the following items: 
one 6 oz (180 mL) cup of coffee, two 12 oz (360 mL) cans of cola, one 12 oz (360mL) cup 
of tea, three 1 oz (85 g) chocolate bars.
18. Prior screen failure, randomization, participation, or enrollment in this study, or prior 
exposure to any  GLP-[ADDRESS_399734] of injection site reaction and injection site injury  assessments.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 27
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
20. Current use of an y medication (including over -the-counter, herbal, or homeopathic 
preparations; with the exception of occasional use of ibuprofen [1.2 g per 24 hou r period] 
or acetaminophen [2 g per 24 hour period]). Current use is defined as use within [ADDRESS_399735] dose, ibuprofen (1.2 g per 24 hour period) or acetaminophen (up to 2 g per 24 hour 
period) may  be administered at the discretion of the investigator or designee.
If deviations occur, the investigator or designee in consultation with the Sponsor if needed will 
decide on a case b y case basis whether the subject may continue participation in the study .
All medications taken b y subjects during the course of the stud y will be recorded.
Use of excluded agents (prescription or nonprescription) or dietary  products is outlined in 
Table 3.
Table 3 Excluded Medications, Supplements, and Dietary Products
CategoryBetween Screening and Randomization 
(Days -28 to predose [Day 1 Period 1])Post-Random ization (Day 1 
Period 1) up to Last PK S ample 
Collection
Alcohol Prohibited from [ADDRESS_399736] PK sample in 
each period 
Xanthine and/or caffeine Prohibited from [ADDRESS_399737]
Subjects are free to withdraw from the study  at any  time for any  reason. 
In addition, subjects may be withdrawn from the study  by [CONTACT_323938]:
A positive pregnancy test for females.
Positive urine drug or alcohol results.
Difficulties in blood collection.
7.[ADDRESS_399738]’s study  participation at any  time during the study  
when the subject meets the study  termination criteria described in Section 7.5. In addition, a 
subject may  discontinue his or her participation without giving a reason at any  time during the 
study . Should a subject’s participation be discontinued, the primary  criterion for termination 
must be recorded b y the investigator. In addition, efforts should be made to perform all 
procedures scheduled for the end -of-study  or early termination as described in Section 3.
7.[ADDRESS_399739] Replacement
Replacement of discontinued or withdrawn subjects due to any  reason will be assessed on a case 
by [CONTACT_323939] a minimum of 14 subjects complete each treatment sequence (per cohort 
weightband) wit hin each cohort of the study .
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 29
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
8. CLINICAL STUDY MATER IAL MANAGEMENT
8.1 Clinical Study Drug 
Teduglutide will be administered as a subcutaneous (SC) injection only . 
Subjects will receive teduglutide in each period either by  a syringe injection ([sy ringe and vial ], 
reference; Treatment A) or a pen injector (test; Treatment B) as single SC fixed doses, based on 
subject weightband assignment (
≥40.0 kg to ≤75.0 kg [Cohort 1] and >75.0 kg to ≤120.0 kg 
[Cohort 2]). 
Cohort [ADDRESS_399740].
8.1.2 Clinical Study Drug Inventory and Storage
The Sponsor will supply  sufficient quantities of teduglutide products, including supplies for 
retention, and pre- filled pen injectors to allow completion of this study . The same lot number 
will be used throughout the study. Full details pertaining to pharmacy  and dosing supplies will be 
described in a separate document.
The lot numbers and expi[INVESTIGATOR_1659] (where available) of the stud y drugs supplied will be 
recorded in the final report. Study  drugs wi ll be stored according to the product labels provided 
with the product.
Records will be made of the receipt, preparation, dispensing, and final disposition of the study  
drug supplied.
8.1.[ADDRESS_399741], according to a 
randomization scheme generated at Celerion. 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 30
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
Subjects will be assigned to a cohort based on their weight and then provided the study 
treatments according to the randomization scheme. I n each cohort, subjects will be randomized 
to1 of 2 sequences and administered a single dose of teduglutide on Day  1 of each period per 
randomization sequences, either AB or BA as outlined in Table 2. To ensure adequate 
distribution across 3 injection sites (ie, thigh, abdomen, and arm), randomization will also be 
stratified by  [CONTACT_323915].
If replacement subjects are used, the replacement subject number will be 100 more than the 
original (eg , Subject No. [ADDRESS_399742] No. 1).
8.1.5 Clinical Study Blind Maintenance/Unblinding Procedure
Not applicable.
8.1.[ADDRESS_399743] accountability  records. 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 31
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
9. STUDY PROCEDURES
9.1 Admin istrative Procedures
9.1.1 Informed Consent Procedure
The purpose of the study , the procedures to be carried out and the potential hazards will be 
described to the subjects in non- technical terms. Subjects will be required to read, sign, and date 
an ICF summariz ing the discussion prior to screening, and will be assured that they  may  
withdraw from the stud y at an y time without jeopardizing their medical care.
Subjects will be given a copy  of their signed ICF.
[IP_ADDRESS]
Assignment of Screening and Allocation Numbers
Each sub ject will be assigned a unique identification number upon screening. Subjects who 
complete the study  screening assessments and meet all the eligibility  criteria will be assigned a 
unique identification number at the time of dosing, different from the scree ning number.
If replacement subjects are used, the replacement subject number will be 100 more than the 
original (eg, Subject No. [ADDRESS_399744] No. 1).
[IP_ADDRESS] Study Drug Assignment
This is a 2- way, crossover study . All subjects will receive study  drugs as detailed in Section 6.1.
9.1.2 Inclusion and Exclusion 
Please refer to Section 7.1and Section 7.2.
9.1.3 Medical History/ Demography
Medical history  and demographic data, including name, s ex, age, race, ethnicity , and history  of 
tobacco use will be recorded.
9.1.4 Concomitant Medications
Concomitant medications will be prohibited as listed in Section 7.3. All medications taken b y 
subjects during the course of the stud y will be recorded.
9.2 Clinical Procedures and Assessments
The Schedule of Stud y Procedures (Section 3) summarizes the clinical procedures to be 
performed at each visit. Individual clinical procedures are described in detail below. Additional 
evaluations/testing may  be deemed necessary  by [CONTACT_1718]/or the Sponsor 
for reasons related to subject safet y.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399745] time point as possible. All other procedures should be completed 
as close to the prescribed/scheduled time as possible, but can be performed prior to or after the 
prescribed/scheduled time.
Any nonscheduled procedures required for urgent evaluation of safet y concerns take precedence 
over all routine scheduled procedures. 
The blood collection time deviation windows are presented below:
Protocol Hour Deviation Window
Predose ≤ -2 minutes (prior to dose)
>0.0 – 8.0 hour ≤ ± 2 minutes
>8.0 – 24.0 hour ≤ ± 5 minutes
9.2.1 Full Physical Examination
A full phy sical examination will be performed at screening and end of Period 2 as outlined in the 
Schedule of Study  Procedures (Section 3). 
An abbreviated ph ysical exam will be performed at check -in for each period and prior to release 
in Period 1. An abbreviated phy sical examination will include at the minimum, examination of 
respi[INVESTIGATOR_696] , cardiovascular, and gastrointestinal s ystems, with the option for further examination 
of additional sy stems as necessary  based on reported sy mptoms/AEs.
Symptom -driven phy sical examinations may  be performed at other times, if deemed necessary  
by [CONTACT_1719].
9.2.2 Height and Weight
Body height (cm) and weight (kg) will be reported as outlined in the Schedule of Study 
Procedures (Section 3).
9.2.3 Body Mass Index (BMI)
BMI will be calculated based on the height and weight measured at screening. If applicable, BMI 
will be recalculated with the subsequent measures of height from screening and the most current 
weight measurement.
9.2.4 Vital Signs
Single measurements of body  temperature, respi[INVESTIGATOR_2842], blood pressure, and heart rate, will 
be measured as outlined in the Schedule of Study Procedures (Sect ion3). Additional vital signs 
may be taken at any  other times, if deemed necessary .
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399746] in a supi[INVESTIGATOR_2547], except 
when they  are seated or semi -reclined because of study  procedures and/or AEs (eg, nausea, 
dizziness) or if deemed necessary  by [CONTACT_1719].
At the predose time points, vital signs will be measured within 24 hours pr ior to dosing in each 
period. When scheduled postdose, vital signs will be performed within approximately  15minutes 
of the scheduled time point.
9.2.5 12- Lead ECG
Single 12- lead ECGs will be performed as outlined in the Schedule of Study  Procedures 
(Section 3). Additional ECGs may  be taken at any other times, if deemed necessary  by [CONTACT_42038].
ECGs will be performed following [ADDRESS_399747]’s eligibility .
9.2.6 Injection Site Reaction and Injection Site Injury Assessments 
Local tolerability
, reactions, and injuries at the injection site will be evaluated by  [CONTACT_1275]/designee as indicated in Section 3. Local tolerability  will be assessed before, during, 
and after the end of the infusion at the time points.
Additionally , Subjects will be instructed to report the development of rash, hives, pruritus, 
flushing, urticaria, injection site pain, redness, bruising, and/or swelling, etc, that may  represent 
an administration
-related reaction or injury  to the study  medication or administration method. 
Subjects will be asked to report AEs to the CRU staff immediatel y as they are experienced. 
Appropriate treatment and follow- up will be determined by  [CONTACT_093]. Subjects with a 
severe or serious administ ration-related reaction (eg, shortness of breath, wheezing, stridor, 
angioedema, life -threatening change in vital signs, severe injection site reactions) must be 
withdrawn from the study and treated and followed up appropriatel y. 
Any injection site reacti on or injury  will be collected and graded as mild, moderate, or severe.
Additional instructions concerning the collection of injection site reactions and injuries will be 
provided to the site prior to study  start.
9.2.[ADDRESS_399748] dose of teduglutide, subjects are to be randomized to a treatment as 
depi[INVESTIGATOR_28071] 1.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 34
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
In each period, subjects will receive teduglutide administered SC to the arm, thigh ,or abdomen 
either b y syringe injection (syringe and vial) or pen injector. The same location (ie, arm, th igh or 
abdomen) but different puncture spot will be used for administration in the subsequent period. 
Time of administration and administration site location will be recorded. 
Additional administration instructions will be provided in a separate document for the test 
injection 
Administration of teduglutide reference will be done according to the full prescribing 
information of teduglutide (GATTEX®, Prescribing Information, 2018).
9.2.8 AE Monitoring
Subjects will be monitored throughout the study  for adverse re actions to the study  drugs and/or 
procedures as described in Section 10.
9.2.9 Laboratory Procedures and Assessments
[IP_ADDRESS] Clinical Laboratory Tests
Hematology
Hematology  will consist of the following tests:
Hem oglobin Red blood cell count
Hem atocrit Platelet count
Total and differential leukocyte count
Chemistry 
Serum chemistry  tests will be performed after at least an [ADDRESS_399749]; however, in case of 
dropouts or rechecks, subjects may  not have fasted for [ADDRESS_399750] serum chemistry  panel:
Blood Urea Nitrogen Albumin
Bilirubin (total and direct) Sodium
Alkali ne phosphatase Potassium
Aspartate aminotransferase (AST) Chloride
Alanine aminotransferase (ALT) Glucose 
Lipase Creatinine *
Amylase
* At screening, creatinine clearance will be calculated using the Cockcroft -Gault formula.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399751] of the following tests:
pH Bilirubin
Specific gravity Blood *
Protein * Nitrite *
Glucose Urobilinogen
Ketones Leukocyte esterase *
* If urinalysis is positive for protein, blood, nitrite and/or leukocyte esterase, a microscopic examination (for red 
blood cells, white blood cells, bacteria, casts, and epi[INVESTIGATOR_1663]) will be performed.
Other 
PCR Test (COVID- 19) Urine drug screen
Opi[INVESTIGATOR_858] (includes morphine, heroin 
(diacetylmorphine), codeine, 6 -acetylmorphine, 
dihydrocodeine, h ydrocodone, thebaine, and, 
hydromorphone)
Amphetamines
Barbiturates
Benzodiazepi[INVESTIGATOR_1651]
Cocaine
CannabinoidsHIV test
HBsAg
HCV (if antibody positive, confirm ribonucleic acid 
negative)
Urine alcohol screen
Female subjects only
Serum human chorionic gonadotropin (hCG) (for 
pregnancy)
FSH (to confirm postmenopausal status, as applicable) 
Coagulation*
Coagulation evaluations will consist of the following tests:
Prothrombin time International normalized ratio (INR)
* To be performed for subjects who develop ALT >3x upper limit of normal (ULN) (See Section [IP_ADDRESS] ).
9.3 PK Samples
Instructions for PK sample collection, processing, and shippi[INVESTIGATOR_323902].
Primary  specimen collection parameters are provided in Table 4.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 36
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
Table 4 Primary Specimen Collections
Specimen NamePrim ary 
SpecimenPrim ary 
Specimen 
Derivative Description of Intended UseSample 
Collection
Plasma sample Plasma Plasma sample for PK 
analysisMandatory
9.3.1 PK Measurements 
The following PK parameters will be calculated from plasma concentrations of teduglutide, 
unless otherwise specified:
Pharm acokinetic Param eter Definition
AUC 0-tlastArea under the concentration curve from time zero to the last measurable 
concentration
AUC 0-∞ Area under the concentration curve extrapolated to infinite time
Cmax Maximum concentration 
tmax Time of first occurrence of Cmax
z Term inal disposition phase rate constant
t½ Term inal disposition phase half-life
CL/FApparent total body clearance for extravascular administration divided by 
[CONTACT_323940]/FApparent volume of distribution associated with the terminal slope 
following extravascular administration divided by [CONTACT_323941] 0-∞, zor t ½will be reported for cases that do not exhibit a terminal log linear 
phase in the concentration time profile.
No PK parameters will be calculated for subjects with 2 or fewer consecutive time points with 
detectable concentrations.
PK parameters will be ca lculated from reliable teduglutide concentration -time profiles using 
non-compartmental methods where all calculations will be based on actual sampling times.
Individual and mean serum concentration time curves (both linear and log linear) will be 
included 
in the final report.
9.3.[ADDRESS_399752] one dose of study  drug (including subjects who terminate the 
study  early) will be contact[INVESTIGATOR_530] b y the CRU 7 (±2) days after the last study drug administration to 
determine if an y AE has occurred since the last study  visit. 
At all times, a subject may be required to remain at the CRU for longer at the discretion of the 
investigator or designee.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399753] who has 
signe d informed consent to participate in a study ; it does not necessarily  have to have a causal 
relationship with the treatment.
An AE can therefore be any  unfavorable and unintended sign (eg, a clinically  significant 
abnormal laboratory  finding), s ymptom, or 
disease temporall y associated with the use of a drug, 
whether or not it is considered related to the drug.
An AE also means any untoward medical occurrence, unintended disease or injury or an y 
untoward clinical signs, including an abnormal laboratory  findi ng, in subjects, users or other 
persons, in the context of a clinical investigation, whether or not related to the investigational 
device.
An untoward finding generall y ma y:
Indicate a new diagnosis or unexpected worsening of a preexisting condition. (Inte rmittent 
events for pre -existing conditions or underly ing disease should not be considered AEs.)
Necessitate therapeutic intervention.
Require an invasive diagnostic procedure.
Require discontinuation or a change in dose of study  medication or a concomitant 
medication.
Be considered unfavorable by  [CONTACT_304531].
Diagnoses versus signs and sy mptoms:
Each event should be recorded to represent a single diagnosis. Accompan ying signs 
(including abnormal laboratory  values or ECG findings) or s ymptoms should NOT be 
recorded as additional AEs. If a diagnosis is unknown, sign(s) or s ymptom(s) should be 
recorded appropriatel y as an AE(s).
Laboratory  values and ECG findings:
Changes in laboratory  values or ECG parameters may be considered AEs if they  are judged to 
be clinically  significant (ie, if some action or intervention is required or if the investigator 
judges the change to be bey ond the range of normal phy siologic fluctuation). A laboratory  
re-test and/or continued monitoring of an abnormal value are not considered an intervention. 
In addition, repeated or additional noninvasive testing for verification, evaluation or 
monitoring of an abnormality  is not considered an intervention.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 39
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
If abnormal laboratory  values or ECG findings are the result of pat hology  for which there is 
an overall diagnosis (eg, increased creatinine in renal failure), the diagnosis only  should be 
reported appropriately  as an AE.
Pre-existing conditions:
A pre -
existing condition (present at the time of signing of informed consent) is considered a 
concurrent medical history  condition and should NOT be recorded as an AE. A baseline 
evaluation (eg, laboratory test, ECG, X -ray, etc) should NOT be recorded as an AE unless 
related to a stud y procedure. However, if the subject experiences a worsening or 
complication of such a concurrent medical history  condition, the worsening or complication 
should be recorded appropriately  as an AE (worsening or complication occurs after informed 
consent is signed). Investigators should ensure that the e vent term recorded captures the 
change in the condition (eg, “worsening of…”).
If a subject has a pre -existing epi[INVESTIGATOR_174343] (eg, asthma, epi[INVESTIGATOR_30989] y), an y occurrence of an 
epi[INVESTIGATOR_304503], se rious, or 
severe in nature, that is, investigators should ensure that the AE term recorded captures the 
change from Baseline in the condition (eg, “worsening of…”).
If a subject has a degenerative concurrent condition (eg, cataracts, rheumatoid arthritis),
worsening of the condition should only  be captured as an AE if occurring to a greater extent 
to that which would be expected. Again, investigators should ensure that the AE term 
recorded captures the change in the condition (eg, “worsening of…”).
Worsening of AEs:
If the subject experiences a worsening or complication of an AE after the first administration 
of study  medication or after an y change in stud y medication, the worsening or complication 
should be recorded as a new AE. Investigators should ensure that the AE term recorded 
captures the change in the condition (eg, “worsening of…”).
Changes in severit y of AEs:
If the subject experiences a change in the severity  of an AE that is not associated with a 
change in study medication or investigational devic e, the event should be captured once with 
the maximum severity  recorded.
Preplanned surgeries or procedures:
Preplanned procedures (surgeries or therapi[INVESTIGATOR_014]) that were scheduled prior to signing of 
informed consent are not considered AEs. However, if a preplanned procedure is performed 
early (eg, as an emergency) due to a worsening of the pre -existing condition, the worsening 
of the condition should be captured appropriatel y as an AE. Complications resulting from 
any planned surgery  should be reported as AEs.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 40
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
Elective surgeries or procedures:
Elective procedures performed where there is no change in the subject’s medical condition 
should not be recorded as AEs but should be documented in the subject’s source documents. 
Complications resulting from an elec tive surgery  should be reported as AEs.
Overdose:
An overdose is defined as a known deliberate or accidental administration of investigational 
drug, to or b y a study subject, at a dose above that which is assigned to that individual subject 
according to th e stud
y protocol. I t is up to the investigator or the reporting phy sician to 
decide whether a dose is to be considered an overdose, in consultation with the Sponsor.
All cases of overdose (with or without associated AEs) will be documented on an Overdose 
page of the case report form (CRF), in order to capture this important safet y information 
consistently  in the database. AEs associated with an overdose will be documented on AE 
CRF(s) according to Section 10.
Serious adverse events (SAEs) of overdose should be reported according to the procedure 
outlined in Section 10.2.7 .
In the event of drug overdose, the subject should be treated s ymptomatically .
10.1.[ADDRESS_399754] medical occurrence that at an y dose:
1. Results in DEATH.
2.Is LIFE THREATENING.
The term “life threatening” refers to an event in which the subject was at risk of death at 
the time of the event; it does not refer to an event that hy pothetically  might have caused 
death if it were more severe.
3.Requires inpatient HOSPI[INVESTIGATOR_117495].
4.Results in persistent or signi ficant DISABILITY/INCAPACI TY.
5.Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6.Is an IMPORTANT MEDI CAL  EVENT that satisfies an y of the following:
May require intervention to prevent items 1 through 5 above.
May expose the subject to danger, even though the event is not immediately  life 
threatening or fatal or does not result in hospi[INVESTIGATOR_059].
Includes an y event or s ynonym described in the [COMPANY_005] Medically  Significant AE L ist 
(Table 5).
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399755]
Term
Acute respi[INVESTIGATOR_1399]/acute respi[INVESTIGATOR_323903] / ventricular fibrillation / ventricular tachycardia Acute liver failure
Malignant hypertension Anaphylactic shock
Convulsive seizures Acute renal failure
Agranulocytosis Pulmonary hypertension
Aplastic anemia Pulmonary fibrosis
Toxic epi[INVESTIGATOR_194]/Stevens -Johnson syndrome Confirmed or suspected endotoxin shock
Neuroleptic malignant syndrome / malignant hyperthermia COVID -19 pneumonia
Confirmed or suspected transmission of infectious agent by a 
medicinal productCOVID -19-related disease
Spontaneous abortion / stillbirth and fetal death
Note: Terms identified on the Medically Significant AE List represent the broad medical concepts to be 
considered as “Important Medical Events” satisfying SAE reporting requirements.
AEs that fulfill 1 or more of the serious criteria above are to be considered SAEs and should be 
reported and followed up in the same manner (see Section 10.1 and Section 10.1.1 ).
10.1.[ADDRESS_399756] had a cecal poly p identified during a colonoscopy  (SHP633- 304). This event was 
reported as an AE of special interest of large intestinal poly p that was assessed as moderate in 
intensity  and related to teduglutide by  [CONTACT_093].
Based on the pharmacologic activity  and findings in animals, teduglutide has the potential to 
cause h yperplastic changes, including neoplasia, in the small bowel and hepatobiliary  tract. 
Further detai ls are provided in the current IB edition. 
10.2 AE Procedures
10.2.1 Assigning Severity/Intensity of AEs
The different categories of severit y/intensity  are:
Mild: An adverse event that is usually  transient and may  require onl y minimal treatment 
or therapeutic intervention. The event does not generall y interfere with usual 
activities of daily  living.
Moderate: An adverse event that is usually  alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily  living , causing 
discomfort but poses no significant or permanent risk of harm to the research 
participant.
Severe: An adverse event that interrupts usual activities of daily  living, or significantly  
affects clinical status, or may  require intensive therapeutic intervention.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 42
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
10.2.2 Assigning Causality of AEs
The relationship of each AE to study  medication(s) will be assessed using the following 
categories:
Related: An AE that follows a reasonable temporal sequence from administration of a drug 
(including the course after withdrawal of the drug), or 
for which a causal 
relationship is at least a reasonable possibility , ie, the relationship cannot be ruled 
out, although factors other than the drug, such as underlying diseases, 
complications, concomitant drugs and concurrent treatments, may  also be 
responsible.
Not 
Related:An AE that does not follow a reasonable temporal sequence from administration 
of a drug and/or tha t can reasonabl y be explained by [CONTACT_1604], such as 
underly ing diseases, complications, concomitant medications and concurrent 
treatments.
10.2.[ADDRESS_399757] signs/s ymptoms were noted by  [CONTACT_3184]/or
investigator.
10.2.[ADDRESS_399758] died.
10.2.5 Pattern of Adverse Event (Frequency) 
Epi[INVESTIGATOR_11742] (eg, headache) or those which occur repeatedl y over a p eriod of consecutive days 
are intermittent. All other events are continuous.
10.2.6 Action Taken With Study Treatment
Drug withdrawn – a study medication is stopped due to the particular AE.
Dose not changed –the particular AE did not require stoppi[INVESTIGATOR_007] a study  medication.
Unknown –only to be used if it has not been possible to determine what action has been 
taken.
Not applicable –a stud y medication was stopped for a reason other than the particular AE 
eg,the study  has been terminated, the subject died, dosing w ith study  medication had not y et 
started or dosing with study  medication was already  stopped before the onset of the AE.
Drug interrupted – the dose was interrupted due to the particular AE.
Outcome 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 43
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
Recovered/resolved –subject returned to first assessmen t status with respect to the AE.
Recovering/resolving –the intensity  is lowered by  [CONTACT_1734]: the diagnosis has or 
signs/sy mptoms have almost disappeared; the abnormal laboratory  value improved, but has 
not returned to the normal range or to the baseline value; the subject died from a cause other 
than the particular AE with the condition remaining “recovering/resolving.”
Not recovered/not resolved –there is no change in the diagnosis, signs or sy mptoms; the 
intensity  of the diagnosis, signs/sy mptoms or laboratory  value on the last day  of the observed 
study  period has become worse than when it started; is an irreversible congenital anomal y; 
the subject died from another cause with the particular AE state remaining “Not 
recovered/not resolved.”
Reco vered/resolved with sequelae –the subject recovered from an acute AE but was left with 
permanent/significant impairment (eg, recovered from a cardiovascular accident but with 
some persisting paresis).
Fatal –an AE that is considered as the cause of death .
Unknown –
the course of the AE cannot be followed up due to hospi[INVESTIGATOR_47350]’s participation in the study .
10.2.[ADDRESS_399759] AEs, and Abnormal 
Liver Function Tests
[IP_ADDRESS] Collect ion Period
Collection of AEs (ie, AEs, SAEs, Special Interest AEs, and Abnormal Liver Function Tests) 
will commence at the time the subject signs the informed consent. Routine collection of AEs will 
continue until the follow -up phone call on Day  8 (±2 day s) of Period 2, approximately  [ADDRESS_399760] discontinues study  
participation. 
[IP_ADDRESS] Reporting AEs
At eac h study  visit and at the follow -up contact, the investigator or designee will assess whether 
any subjective AEs have occurred. A neutral question, such as “How have you been feeling since 
your last visit?” may  be asked. Subjects may  report AEs occurring at any other time during the 
study . Subjects experiencing an SAE prior to the first exposure to investigational product must 
be monitored until the symptoms subside and any  clinically  relevant changes in laboratory values 
have returned to Baseline or there is a satisfactory  explanation for the change. Nonserious AEs 
that begin prior to the first exposure to investigational product, related or unrelated to the stud y 
procedure, need not be followed-up for the purposes of the protocol.
All subjects experiencing AEs, whether considered associated with the use of the study  
medication or not, must be monitored until the symptoms subside and any  clinically  relevant 
changes in laboratory  values have returned to Baseline or until there is a satisfactory  explanation 
forthe changes observed. 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 44
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
AllAEs willbedocumented intheAEpage oftheCRF, whether or not the investigator 
concludes that the event is related to the drug treatment. The following information will be 
documented for each event:
Event term.
Start and end date and time.
Pattern of AE (frequency).
Severity /Intensity .
Causality  (Investigator’s opi[INVESTIGATOR_304506][s]).
Action taken with study  drug.
Outcome of event.
Seriousness.
[IP_ADDRESS] Reporting SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
procedure outlined below:
A [COMPANY_005] SAE form must be completed, in English and signed by  [CONTACT_43054] y 
or within [ADDRESS_399761] onset or notification
of the event. The information should be 
completed as full y as possible but contain, at a minimum:
A short description of the event and the reason why the event is categorized as serious.
Subject identification number.
Investigator’s name.
Name [CONTACT_323955] y medication(s).
Causality  assessment.
The SAE form should be transmitted within [ADDRESS_399762] report becomes available at a later date, the 
investigator should complete a follow -up SAE form or provide other written documentation and 
fax it immediately  within 24 hours of receipt. Copi[INVESTIGATOR_323904] 
(eg, ECGs, laboratory  tests, discharge summary , postmortem results) should be sent to the 
addressee, if requested.
All SAEs should be followed up until resolution or permanent outcome of the event. The 
timelines and procedure for follow-
up reports are the same as those for the initial report.
[IP_ADDRESS] Reporting Special Interest AEs 
Occurrence of AEs of special interest as outlined in Section 10.1.2 will be reported directly  to the 
Sponsor.
[IP_ADDRESS] Close Monitoring and Treatment Discontinuation for Potential 
Drug -Induced Liver Injury (DILI)
Subjects who develop ALT >3x UL N after first dosing administration should be monitored 
closely  and the clinical significance of the elevation should be assessed by  [CONTACT_093]. Close 
observation includes the following:
Repeating liver enz yme and serum bilirubin tests two or three times weekl y. Frequenc y of 
retesting can decrease to once a week or less if abnormalities stabilize or the study  drug has 
been discontinued and the subject is as ymptomatic. 
Obtaining a more detailed history  of symptoms and prior or concurrent diseases. 
Obtaining a history  of concomitant drug use (including nonprescription medications and 
herbal and dietary  supplement preparations), alcohol use, recreational drug use, and special 
diets. 
Ruling out acute viral hepatitis ty pes A, B, C, D, and E; autoimmune or alcoholic hepatitis; 
Nonalcoholic steatohepatitis; hypoxic/ischemic hepatopathy ; and biliary  tract disease. 
Obtaining a history  of exposure to environmental chemical agents. 
Obtaining additional tests to evaluate liver function, as appropriate (eg, i nternational 
normalized ratio [I NR], direct bilirubin). 
Considering gastroenterology  or hepatology  consultations. 
If a subject develops an y of the following after the first dose, treatment should be discontinued, 
the medical monitor should be contact[INVESTIGATOR_530] i mmediately , and the subject should be withdrawn from 
the study : 
ALT or AST >8xULN
ALT or AST >5xULN at the end of the 7 day  washout period
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 46
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
ALT or AST >3xULN and (total bilirubin >2xULN or INR >1.5)
ALT or AST >3xULN with the appearance of fatigue, nausea, vomiting, right upper quadrant 
pain or tenderness, fever, rash, and/or eosinophilia (>5%)
All subjects showing possible DILI should be followed until all abnormalities return to normal or 
to the baseline state. Pertinent elements of the case should be cap tured in the DILI CRF. 
10.2.8
Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities 
The Sponsor will be responsible for reporting all suspected unexpected serious adverse reactions 
(S[LOCATION_003]Rs) and an y other applicable SAEs to regulatory autho rities, investigators and IRBs or 
IECs, as applicable, in accordance with national regulations in the countries where the stud y is
conducted. Relative to the first awareness of the event by /or further provision to the Sponsor or 
Sponsor’s designee, S[LOCATION_003]Rs will be submitted within [ADDRESS_399763] a cop y of all 
expedited reports to his or her IRB or IEC in accordance with national regulations.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 47
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
11.
STATISTICAL METHODS
11.1 Statistical and Analytical Plans
Detailed methodology  for summary  and statistical anal yses of the data collected in this study  will 
be documented in a statistical anal ysis plan (SAP). The SAP will be prepared and finalized 
before database lock. A separate PK anal ysis plan will be finalized prior to database lock. These 
documents will provide further details regarding the definition of anal ysis variables and anal ysis 
methodology  to address all study  objectives. Additional statistical analy ses other than those 
described in this section may  be performed if deemed appropriate.
11.1.1 Analysis Sets
[IP_ADDRESS] PK Set
All subjects who comply  suffi ciently  with the protocol and display  an evaluable PK profile for 
both periods (exposure to treatment, availabilit y of measurements, completion of washout period, 
and absence of major protocol violations) will be included in the statistical anal yses.
[IP_ADDRESS] Safet y Set
All subjects who received at least one dose of the study  drug will be included in the safet y 
evaluations.
11.1.2 Analysis of Demography and Other Baseline Characteristics
Continuous demographic data (ie, age, weight, height, and BMI will be listed and summa rized 
using appropriate summary statistics. Categorical demographic data (ie, gender, race, and 
ethnicity ) will also be listed and tabulated.
11.1.[ADDRESS_399764] occurrence of C maxis reached (t max) will be also 
listed for each subject and treatment and summarized by  [CONTACT_7864], minimum and maximum 
grouped b y treatment and cohort. The number of time points of the termi nal log- linear phase 
used to estimate the terminal rate constant ( z) and the residual area will be also provided for 
each subject and treatment. 
Individual concentration -time curves will be presented in linear/linear and log/linear scale. 
Figures showing the mean (with ±SD as error bars) as well as the median (with 25thto 75th
quantiles as error bars) concentration time profiles grouped by  [CONTACT_323942]/linear and log/linear scale. The PKendpoints will also be anal yzed by 
[CONTACT_93403] (ie, thigh, abdomen, and arm) .
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399765], AUC 0-∞, and C max, will be anal yzed using an ANOVA model for each 
cohort separatel y. 
PK metrics will be transformed prior to anal ysis using a logarithm ic transformation. The 
difference in means and the corresponding two- sided 90% CI on the log -transformed scale will 
be obtained from that model. The difference in means and the corresponding CI will be 
back -transformed to obtain the ratio of geometric mean s and the corresponding two -sided 
90% CI for the ratio on the original scale. The terms used in the ANOVA model will be 
sequence, subject within sequence, period and treatment. According to EMA guideline 
(CPMP/EWP/QWP/1401/98 Rev. 1/ Corr) (EMA 2010), subj ects who will not provide evaluable 
data for both periods will not be included and fixed effects will be used for all terms.
To assess bioavailability  between test and reference, the 90% CI for the ratio of geometric means 
for PK metrics, AUC 0-tlast, AUC 0-∞, and Cmaxwill be derived and compared (and would be 
contained within the acceptance interval of 80.00 to 125.00% if bioequivalent).
11.1.[ADDRESS_399766] and summarized by  [CONTACT_323943].
11.2 Interim Analysis and Criteria for Early Termination
Not applicable.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 49
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
11.3
Determination of Sample Size
The overall power for the endpoints (AUC 0-tlast, AUC 0-∞, and C max) with a total sample size of 
64subjects will be 92.6% power based on a 5% type 1 error and a Coefficient of Variation of 
21%, assuming a true ratio of test/reference of 1.0 in their relative bio -availabilities based on the 
acceptance interval of 80.00 to 125.00%. The sample size of 28 subjects within each cohort 
(14each sequence) was accounted for approximately  10% potential drop -outs and/or 
non-reliable concentration time -profiles to y ield 32 subjects per cohort ([ADDRESS_399767] s per sequence 
within each cohort). This sample size was calculated with SAS v9.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399768] igator and 
study  site guarantee access to source documents by
 [CONTACT_4885] (contract research 
organization) and b y the IRB or IEC.
All aspects of the stud y and its documentation will be subject to review b y the Sponsor or the 
Sponsor’s desig nee (as long as blinding is not jeopardized), including but not limited to the 
Investigator’s Binder, study  drug, subject medical records, informed consent documentation, and 
review of CRFs and associated source documents. I t is important that the investig ator and other 
study  personnel are available during the monitoring visits and that sufficient time is devoted to 
the process.
12.[ADDRESS_399769] to study  subjects. Should other unexpected circumstances arise that will 
require deviation from protocol- specified procedures, the investigator should consult with the 
Sponsor or designee (and I RB or IEC, as required) to determine the appropriate course o f action. 
There will be no exemptions (a prospectively  approved deviation) from the inclusion or 
exclusion criteria.
For COVID -19-related protocol deviations, the specific protocol deviation, the reason for the 
deviation, and the relationship to COVI D-
[ADDRESS_399770] the site in advance to arrange an 
auditing visit. The auditor may  ask to visit the facilities where laboratory  samples are collected, 
where the medication is stored and prepared, and any  other facility  used during the stud y. In 
addition, there is the possibility  that this study  may be inspected b y regulat ory agencies, 
including those of foreign governments (eg, the FDA, the [LOCATION_008] Medicines and 
Healthcare products Regulatory  Agency , the Pharmaceuticals and Medical Devices Agency  of 
Japan). If the stud y site is contact[CONTACT_63224] a regulatory  body , the Sponsor should 
be notified immediately . The investigator guarantees access for quality  assurance auditors to all 
study  documents as described in Section 12.1.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399771] for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration of 
Helsinki, and the International Council on Harmonisation (I CH) Harmonised Tripartite 
Guideline for GCP. Each investigator will conduct the study  according to applicable local or 
regional regulatory  requirements and align his or her conduct in accordance with the 
“Responsibil ities of the Investigator” that are listed in Appendix A . The principles of Helsinki 
are addressed through the protocol and through appendices containing requiremen ts for informed 
consent and investigator responsibilities.
13.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local 
requirements of each participating region. The Sponsor or designee will require documentation 
noting all names and titles of members who make up the respective IRB or IEC. If any  member 
of the I RB or IEC has direct participation in this study , written notification regarding his or her 
abstinence from voting must also be obtained. Thos e Americas sites unwilling to provide names 
and titles of all members due to privacy  and conflict of interest concerns should instead provide a 
Federal Wide Assurance Number or comparable number assigned b y the Department of Health 
and Human Services.
The Sponsor or designee will supply  relevant documents for submission to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the IB, a cop y of the informed consent 
form, and, if applicable, subject recruitment materials and/or adve rtisements and other 
documents required b y all applicable laws and regulations, must be submitted to a central or 
local I RB or IEC for approval. The IRB’s or IEC’s written approval of the protocol and subject 
informed consent must be obtained and submitted to the Sponsor or designee before 
commencement of the study  (ie, before shipment of the Sponsor -supplied drug or study  specific 
screening activity ). The IRB or IEC approval must refer to the study  by [CONTACT_1764], 
number, and version date; identif y versions of other documents (eg, informed consent form) 
reviewed; and state the approval date. The Sponsor will ship drug/notify  site once the Sponsor 
has confirmed the adequacy  of site regulatory  documentation and, when applicable, the Sponsor 
has recei ved permission from competent authorit y to begin the stud y. Until the site receives 
drug/notification no protocol activities, including screening, may  occur.
Sites must adhere to all requirements stipulated by  [CONTACT_1765]. This may  include 
notification to the I RB or I EC regarding protocol amendments, updates to the informed consent 
form, recruitment materials intended for viewing by  [CONTACT_1766], local safety  reporting requirements, 
reports and updates regarding the ongoing review of the study  at intervals specified by  [CONTACT_39820], and submission of the investigator’s final status report to I RB or IEC. All 
IRB and IEC approvals and relevant documentation for these items must be provided to the 
Sponsor or its designee.
Subject incent ives should not exert undue influence for participation. Pay ments to subjects must 
be approved b y the IRB or IEC and Sponsor.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399772] authorization form (if 
applicable), and subject information sheet (if ap
plicable) describe the planned and permitted 
uses, transfers, and disclosures of the subject’s personal and personal health information for 
purposes of conducting the study . The informed consent form and the subject information sheet 
(if applicable) furthe r explain the nature of the study , its objectives, and potential risks and 
benefits, as well as the date informed consent is given. The informed consent form will detail the 
requirements of the participant and the fact that he or she is free to withdraw at any time without 
giving a reason and without prejudice to his or her further medical care.
The investigator is responsible for the preparation, content, and IRB or IEC approval of the 
informed consent form and, if applicable, the subject authorization for m. The informed consent 
form, subject authorization form (if applicable), and subject information sheet (if applicable) 
must be approved b y both the I RB or IEC and the Sponsor prior to use.
The informed consent form, subject authorization form (if applicab le), and subject information 
sheet (if applicable) must be written in a language fully  comprehensible to the prospective 
subject. I t is the responsibility  of the investigator to explain the detailed elements of the informed 
consent form, subject authorization form (if applicable), and subject information sheet (if 
applicable) to the subject. I nformation should be given in both oral and written form whenever 
possible and in the manner deemed appropriate by [CONTACT_941] I RB or IEC. In the event the subject is not 
capable of rendering adequate written informed consent, then the subject’s legally  acceptable 
representative may  provide such consent for the subject in accordance with applicable laws and 
regulations.
The subject, or the subject’s legall y acceptable represent ative, must be given ample opportunity  
to: (1) inquire about details of the study, and (2) decide whether or not to participate in the study . 
If the subject, or the subject’s legally acceptable representative, determines he or she will 
participate in the s tudy, then the informed consent form and subject authorization form (if 
applicable) must be signed and dated b y the subject, or the subject’s legall y acceptable 
representative, at the time of consent and prior to the subject entering into the study . The su bject 
or the subject’s legally  acceptable representative should be instructed to sign using their legal 
names, not nicknames, using blue or black ballpoint ink. The investigator must also sign and date 
the informed consent form and subject authorization (i f applicable) at the time of consent and 
prior to subject entering into the study ; however, the Sponsor may  allow a designee of the 
investigator to sign to the extent permitted by  [CONTACT_1289].
Once signed, the original informed consent form, subject aut horization form (if applicable), and 
subject information sheet (if applicable) will be stored in the investigator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copi[INVESTIGATOR_323905], the signed subject authorization 
form (if applicable), and subject information sheet (if applicable) shall be given to the subject.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399773]’s legall y acceptable representative in the same manner as the original informed 
consent. The date the revised consent was obtained should be recorded in the subject’s medical 
record, and the subject should receive a cop y of the revised informed consent form.
13.[ADDRESS_399774]’s right to protection 
against invasion of privacy . Throughout this study , a subject’s source data will only  be linked to 
the Sponsor’s clinical s tudy database or documentation via a unique identification number. As 
permitted by  [CONTACT_1763], limited subject attributes, such as sex, age, or 
date of birth, and subject initials may  be used to verify  the subject and accuracy  of the subject’s 
unique identification number.
To comply  with ICH Guidelines for GCP and to verify  compliance with this protocol, the 
Sponsor requires the investigator to permit its monitor or designee’s monitor, representatives 
from an y regulatory  authority  (eg, FDA, Medicines and Healthcare products Regulatory  Agency , 
Pharmaceuticals and Medical Devices Agency ), the Sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
documents), inc luding, but not limited to, laboratory test result reports, ECG reports, admission 
and discharge summaries for hospi[INVESTIGATOR_1684] a subject’s study  
participation, and autopsy  reports. Access to a subject’s original medical records require s the 
specific authorization of the subject as part of the informed consent process (see Section 13.2).
Copi[INVESTIGATOR_124405] y subject source documents that are provided to th e Sponsor must have certain 
personall y identifiable information removed (ie, subject name, address, and other identifier fields 
not collected on the subject’s CRF).
13.[ADDRESS_399775] results and all data derived 
by [CONTACT_87853] . During and after the study , only the Sponsor may make stud y 
information available to other study  investigators or to regu latory  agencies, except as required b y 
law or regulation. Except as otherwise allowable in the clinical study  site agreement, an y public 
disclosure (including publicly  accessible websites) related to the protocol or study  results, other 
than study  recruitm ent materials and/or advertisements, is the sole responsibility  of the Sponsor.
The Sponsor may  publish any  data and information from the study  (including data and 
information generated by [CONTACT_093]) without the consent of the investigator. Manuscri pt 
authorship for an y peer -reviewed publication will appropriately reflect contributions to the 
production and review of the document. All publications and presentations must be prepared in 
accordance with this section and the Clinical Study Site Agreement . In the event of an y 
discrepancy  between the protocol and the Clinical Study  Site Agreement, the Clinical Study Site 
Agreement will prevail.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 54
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
13.4.2 Clinical Study Registration 
In order to ensure that information on clinical trials reaches the public in a timely manner and to 
comply  with applicable laws, regulations and guidance, [COMPANY_005] will, at a minimum register all 
interventional clinical trials it sponsors any where in the world on ClinicalTrials.gov and/or other 
publicly  accessible websites before start of st udy, as defined in [COMPANY_005] Policy /Standard. [COMPANY_005] 
contact [CONTACT_3031], along with investigator’s city , state (for American investigators), country , 
and recruiting status will be registered and available for public viewing. 
For some registries, [COMPANY_005] will assist callers in locating stud y sites closest to their homes by 
[CONTACT_4206], address, and phone number to the callers requesting stud y 
information. Once subjects receive investigator contact [CONTACT_3031], they  may  call the site 
request ing enrollment into the study . The investigative sites are encouraged to handle the study  
inquiries according to their established subject screening process. If the caller asks additional 
questions bey ond the topic of study  enrollment, they  should be refer red to the Sponsor.
Any investigator who objects to the Sponsor providing this information to callers must provide 
the Sponsor with a written notice requesting that their information not be listed on the registry  
site.
13.4.[ADDRESS_399776] the results of clinical trials on ClinicalTrials.gov or other publicly accessible 
websites, as required b y [COMPANY_005] Policy /Standard, applicable laws and/or regulations.
13.[ADDRESS_399777] is participating. If a local underwriter is required, then the Sponsor or 
Sponsor’s designee will obtain clinical study  insurance against the risk of injury  to study  
subjec ts. Refer to the study  site agreement regarding the Sponsor’s policy  on subject 
compensation and treatment for injury . If the investigator has questions regarding this policy , he 
or she should contact [CONTACT_13679]’s designee.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399778] Type / Role Contact
[CONTACT_323944]: 
E-mail: 
14.1.[ADDRESS_399779] Information –Product Quality Complaint 
Contact [CONTACT_39764] / Role Contact
[CONTACT_323945]:
E-mail: 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399780] read and that I understand this protocol, the Investigator’s Brochure, 
package insert and any  other product information provided b y the Sponsor. I  agree to conduct 
this study  in accordance with the requirements of this protocol and also to protect the rights, 
safet y, privacy , and well -being of stud y subjects in accordance with the followin g:
The ethical principles that have their origin in the Declaration of Helsinki.
International Council on Harmonisation, E6(R2) Good Clinical Practice: Consolidated 
Guideline.
All applicable laws and regulations, including, without limitation, data privacy laws and 
regulations.
Regulatory  requirements for reporting serious adverse events defined in Section 10.2.8 of this 
protocol.
Terms outlined in the study  site agreement.
Responsibilities of the I nvestigator ( Appendix A ).
I further authorize that my  personal information may  be processed and transferred in accordance 
with the uses contemplated in Appendix C of this protocol.
Signature [CONTACT_178088] (print or ty pe)
Investigator’s Title
Location of Facility  (City , State/Province)
Location of Facility  (Country )
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399781] Aspartate aminotransferase
AUC Area under the concentration -time curve
AUC 0-∞ Area under the concentration curve extrapolated to infinite time
AUC 0-tlast The area under the concentration -time curve, from time [ADDRESS_399782] quantifiable 
concentration, as calculated by [CONTACT_1690] -log trapezoidal method.
BMI Body  mass index
CFR Code of Federal Regulations
CI Confidence interval
cm Centimeter
Cmax Maximum observed concentration 
COVID -19 Coronavirus Disease 2019
CRF Case report form
CRU Clinical Research Unit
DNA Deoxyribonucleic acid 
DILI drug-induced liver injury 
ECG Electrocardiogram
EU European Union
FSH Follicle stimulating hormone
g Gram
GCP Good Clinical Practice
GLP -
2 Glucagon -like peptide 2
HBsAg Hepatitis B surface antigen
hCG Human chorionic gonadotropin
HCV Hepatitis C virus 
HIV Human immunodeficiency virus
IB Investigator’s Brochure 
ICF Informed Consent Form
ICH International Council for Harmonisation
ID Identifier
IEC Independent Ethics Committee
INR International normalized ratio
IRB Institutional Review Board
kg Kilogram
m2Meters squared
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 58
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
MedDRA®Medical Dictionary for Regulatory Activities®
mg Milligram
min Minute
mL Milliliter
mmHg Millimeter of mercury
msec Millisecond
oz Ounce 
PCR Polymerase chain reaction
PK Pharm acokinetic(s)
PS Parenteral support
QTcF QT interval corrected for heart rate using Fridericia’s formula
SAE Serious adverse event
SAP Statistical analysis plan
SARS -CoV-[ADDRESS_399783] Upper limit of normal
US [LOCATION_002]
[LOCATION_003] [LOCATION_002] of America
λz Term inal disposition phase rate constant
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 59
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
15. DATA HANDLING AND RE CORDKEEPI[INVESTIGATOR_323906]. AEs, medical history, and concurrent conditions will be coded using the Medical 
Dictionary  for Regulatory  Activities (MedDRA®). Drugs will be coded using the World Heal th 
Organization Drug Dictionary .
15.1 CRFs (Electronic and Paper)
Completed CRFs are required for each subject who signs an informed consent.
The Sponsor or its designee will supply investigative sites with access to CRFs. The Sponsor 
willmake arrangements to train appropriate site staff in the use of the CRF. These forms are 
used to transmit the information collected in the performance of this study  to the Sponsor and 
regulatory  authorities. CRFs must be completed in English. Data are transcribed directly  onto
CRFs.
After completion of the entry  process, computer logic checks will be run to identify  items, such 
as inconsistent dates, missing data, and questionable values. Queries may  be issued by  [CONTACT_1748] (or designees) and will be answered b y the site.
Corrections are recorded in an audit trail that captures the old information, the new information, 
identification of the person making the correction, the date the correction was made, and the 
reason for change. Reasons for significant corrections should additionally  be included. 
The investigator must review the CRFs for completeness and accuracy  and must sign and date 
the appropriate CRFs as indicated. Furthermore, the investigator must retain full responsibility  
for the accuracy  and authenticity  of all data entered on the CRFs .
After the l ock of the c linical study database, an y change of, modification of, or addition to the 
data on the CRFs should be made b y the investigator with use of change and modification 
records of the CRFs. The I nvestigator must review the data change for completeness and 
accuracy , and must sign and date . 
CRFs will be reviewed for completeness and acceptability  at the study  site during periodic visits 
by [CONTACT_39810]. The Sponsor or its designee will be permitted to review the subject’s medical 
and hospi[INVESTIGATOR_47354]. The completed CRFs 
are the sole propert y of the Sponsor and should not be made available in any form to third 
parties, except for authorized representatives of ap propriate governmental health or regulatory  
authorities, without written permission of the Sponsor.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399784] Retention
The investigator agrees to keep the records stipulated in Section 15.1 and those documents that 
include (but are not limited to) the study -specific documents, the identification log of all 
participating subjects, medical records, temporary media such as thermal sensitive paper, source 
worksheets, all ori ginal signed and dated informed consent forms, subject authorization forms 
regarding the use of personal health information (if separate from the informed consent forms),
electronic cop y of CRFs, including the audit trail, and detailed records of drug disposition to 
enable evaluations or audits from regulatory  authorities, the Sponsor or its designees. Any  source 
documentation printed on degradable thermal sensitive paper should be photocopi[INVESTIGATOR_323907]’s chart to ensure long -term legibility . Furthermore, ICH 
E6 Section 4.9.5 requires the investigator to retain essential documents specified in I CH E6 
(Section 8.0) until at least 
[ADDRESS_399785] 
2years after the investigation is discontinued and regulatory  authorities are notified. I n addition, 
ICH E6 Section 4.9.5 states that the study  records should be retained until an amount of time 
specified b y applicable regulatory  requirements or for a time specified in the Clinical Study  Site 
Agreement between the investigator and Sponsor.
Refer to the Clinical Study  Site Agreement for the Sponsor’s requirements on record retention. 
The investigator and the head of the institution should contact [CONTACT_304541] y such documents.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399786], J. & Mortensen, P. B. 2005. Teduglutide (ALX-
0600), a dipeptidyl peptidase IV resistant glucagon- like peptide 2 analogue, improves 
intestinal function in short bowel sy ndrome patients. Gut, 54, 1224-31.
Mardini, H. E. & de Villiers, W. J. 2008. Tedu glutide in intestinal adaptation and repair: light at 
the end of the tunnel. Expert Opin Investig Drugs, 17, 945-51.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399787] to I CH GCP and all the applicable 
local laws and regulations. The responsibilities imposed on investigators b y the FDA are 
summarized in the “Statement of Investigator” (Form FDA 1572), which must be completed and 
signed before the investigator may  participate in this study .
The investigat or agrees to assume the following responsibilities by  [CONTACT_2960] a Form FDA 1572:
1.Conduct the study  in accordance with the protocol.
2.Personally  conduct or supervise the staff that will assist in the protocol.
3.If the investigator/institution retains the servic es of any  individual or part y to perform 
study -related duties and functions, the investigator/institution should ensure that this 
individual or party  is qualified to perform those study -related duties and functions and should 
implement procedures to ensure the integrit y of the study -related duties and functions 
performed and an y data generated.
4.Ensure that study  related procedures, including study  specific (nonroutine/nonstandard panel) 
screening assessments are NOT performed on potential subjects, prior to the receipt of 
written approval from relevant governing bodies/authorities.
5.Ensure that all colleagues and employ ees assisting in the conduct of the study  are informed 
of these obligations.
6.Secure prior approval of the study  and any  changes by  [CONTACT_323946]/IEC that conform 
to 21 CFR Part 56, I CH, and local regulatory  requirements.
7.Ensure that the IRB/IEC will be responsible for initial review, continuing review, and 
approval of the protocol. Promptly  report to the IRB/IEC all changes in research acti vity and 
all anticipated risks to subjects. Make at least y early  reports on the progress of the study  to 
the IRB/IEC, and issue a final report within [ADDRESS_399788]’s medical chart. Valid informed consent is the most current 
version approved b y the IRB/IEC . Each informed consent form should contain a subject 
authorization section that describes the uses and disclosures of a subject’s personal 
information (including personal health information) that will take place in connection with 
the study . If an informe d consent form does not include such a subject authorization, then the 
investigator must obtain a separate subject authorization form from each subject or the 
subject’s legall y acceptable representative.
10.Prepare and maintain adequate case histories of all persons entered into the study , including 
CRFs, hospi[INVESTIGATOR_1097], laboratory  results, etc., and maintain these data for a minimum of 
2years following notification by  [CONTACT_323947]. 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399789]:
1.A statement that the study involves research.
2.An explanation of the purposes of the research.
3.The e xpected duration of the subject’s participation.
4.A description of the procedures to be followed, including invasive procedures.
5.The identification of an y procedures that are experimental.
6.The estimated number of subjects involved in the study .
7.A description of the subject’s responsibilities.
8.
A description of the conduct of the study.
9.A statement describing the treatment(s) and the probability  for random assignment to each 
treatment.
10.A description of the possible side effects of the treatment that the subject may  receive.
11.A description of an y reasonably  foreseeable risks or discomforts to the subject and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A description of an y benefits to the subject or to others that reasonabl y may be expected from 
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13. Disclosures of appropriate alternative procedures or courses of treatment, if an y, that might 
be advantageous to the subject and their important potential risks and benefits.
14.A statement describing the extent to which confidentiality  of records identify ing the subject 
will be maintained, and a note of the possibility  that regulatory  agencies, auditor(s), 
IRB/IEC, and the monitor may  inspe ct the records. By  [CONTACT_2960] a written informed consent 
form, the subject or the subject’s legall y acceptable representative is authorizing such access.
15.For research involving more than minimal risk, an explanation as to whether an y 
compensation and an expla nation as to whether any  medical treatments are available if injury  
occurs and, if so, what they  consist of or where further information may  be obtained.
16.The anticipated prorated pay ment(s), if any , to the subject for participating in the study .
17.The antici pated expenses, if any , to the subject for participating in the study.
18.An explanation of whom to contact [CONTACT_39831] 
(investigator), subject’s rights, and IRB/IEC and whom to contact [CONTACT_44751] a research -
related injury  to the subject.
19.A statement that participation is voluntary , that refusal to participate will involve no penalt y 
or loss of benefits to which the subject otherwise is entitled, and that the subject or the 
subject’s legall y acceptable representat ive may  discontinue participation at any  time without 
penalty  or loss of benefits to which the subject is otherwise entitled.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399790]’s decision to withdraw from the research and procedures for 
orderl y termination of participation by  [CONTACT_423].
21. A statement that the subject or the subject’s legally acceptable representative will be 
informed in a timely  manner if information becomes available that may  be relevant to the 
subject’s willingness to continue participation in the study .
22.A statement that results of PGx analy sis will not be disclosed to an individual, unless 
prevailing laws require the Sponsor to do so.
23.The foreseeable circumstances or reasons under which the subject’s participation in the study  
may be terminated.
24.A written sub ject authorization (either contained within the informed consent form or 
provided as a separate document) describing to the subject the contemplated and permissible 
uses and disclosures of the subject’s personal information (including personal health 
infor mation) for purposes of conducting the study. The subject authorization must contain the 
following statements regarding the uses and disclosures of the subject’s personal 
information:
a)that personal information (including personal health information) may  beprocessed b y or 
transferred to other parties in other countries for clinical research and safety reporting 
purposes, including, without limitation, to the following: (1) [COMPANY_005], its affiliates, and 
licensing partners; (2) business partners assisting [COMPANY_005], its affiliates, and licensing 
partners; (3) regulatory  agencies and other health authorities; and (4) IRBs/IECs;
b)it is possible that personal information (including personal health information) may be 
processed and transferred to countries that do not have data protection laws that offer 
subjects the same level of protection as the data protection laws within this country ; 
however, [COMPANY_005] will make every
 effort to keep your personal information confidential, 
and y our name [CONTACT_323956] b y law;
c)that personal information (including personal health information) may  be added to 
[COMPANY_005]’s research databases for purposes of developi[INVESTIGATOR_007] a better understanding of the 
safet y and effectiveness of the study medication(s), stu dying other therapi[INVESTIGATOR_39759], 
developi[INVESTIGATOR_007] a better understanding of disease, and improving the efficiency  of future 
clinical studies;
d) that subjects agree not to restrict the use and disclosure of their personal information 
(including personal health information) upon withdrawal from the study  to the extent that 
the restricted use or disclosure of such information may  impact the scientific integrit y of 
the research; and
e)that the subject’s identity will remain confidential in the event that study  results are 
published.
25. Female subjects of childbearing potential (eg, nonsterilized, premenopausal female subjects) 
who are sexually  active with a nonsterilized male partner must use highl y effective 
contraception (as defined in the informed consent) from signing the informed consent and 
throughout the duration of the study , and for at least [ADDRESS_399791] use highly effective contraception (as defined in the informed consent) from 
signing the informed consent throughout the duration of the study  and for at least [ADDRESS_399792] and retain personal information of investigator, including his or her name, 
address, and other personally  identifiable information. I n addition, investigator’s personal 
information may  be transferred to other parties located in countries throughout the world (eg, the 
United K ingdom, [LOCATION_002], and Japan), including the following:
[COMPANY_005], its affiliates, and licensing partners.
Business partners assisting [COMPANY_005], its affiliates, and licensing partners.
Regulatory  agencies and other health authorities.
IRBs and IECs.
Investi gator’s personal information may  be retained, processed, and transferred b y [COMPANY_005] and 
these other parties for research purposes including the following:
Assessment of the suitability  of investigator for the study  and/or other clinical studies.
Management, monitoring, inspection, and audit of the study .
Analy sis, review, and verification of the study  results.
Safety  reporting and pharmacovigilance relating to the study .
Preparation and submission of regulatory  filings, correspondence, and communications to 
regulatory  agencies relating to the study .
Preparation and submission of regulatory  filings, correspondence, and communications to 
regulatory  agencies relating to other medications used in other clinical studies that may  
contain the same chemical compound present in the study  medication.
Inspections and investigations by  [CONTACT_323948].
Self-
inspection and internal audit within [COMPANY_005], its affiliates, and licensing partners.
Archiving and audit of study  records.
Posting investi gator site contact [CONTACT_3031], study details and results on publicly  accessible 
clinical trial registries, databases, and websites.
Investigator’s personal information may  be transferred to other countries that do not have data 
protection laws that offer the same level of protection as data protection laws in investigator’s 
own country .
Investigator acknowledges and consents to the use of his or her personal information by  [CONTACT_47407].
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399793] dose of study  
drug, nonsterilized** male subjects who are sexually  activ e with a female 
partner of childbearing potential* must use barrier contraception (eg, condom with or without 
spermicidal cream or jelly ). In addition, they  must be advised not to donate sperm during this 
period.
Female Subjects and Their Male Partners
From signing of informed consent, throughout the duration of the study , and for at least [ADDRESS_399794] dose of study  drug , female subjects of childbearing potential* who are sexually active 
with a nonsterilized male partner** must use a highly  effective/ effective method of contraception 
(from the list below). 
In addition they  must be advised not to donate ova during this period.
Definitions and Procedures for Contraception and Pregnancy Avoidance
* A woman is considered a woman of childbearing potential, ie fertile, following menarche and 
until becoming post -menopausal unless permanently  sterile. Permanent sterilization methods 
include hy sterectomy  and bilateral oophorectomy. A postmenopausal state is defined as no 
menses for 12 months without an alternative medical cause. A high FSH level in the 
postmenopausal range (FSH>40 IU/L) may  be used to confirm a post -menopausal state in 
younger women (eg, those <45 y ear old) or women who are not using hormonal contraception or 
hormonal replacement therap y. Howeve r, in the absence of 12 months of amenorrhea, a single 
FSH measurement is insufficient.
** Sterilized males should be at least [ADDRESS_399795] had bilateral 
orchidectom y.
The following apply for contraception and pregnancy avoidance.
1.Highl y effective methods of contraception are defined as “those, alone or in combination, 
that result in a low failure rate (ie, less than 1% failure rate p er year when used consistently  
and correctl y). The only acceptable methods of contraception are: 
Non-Hormonal Methods: 
–Intrauterine device (IUD).
–Bilateral tubal ligation.
– Vasectomised partner (provided that partner is the sole sexual partner of the stud y 
subjects and that the vasectomised partner has received medical assessment of the 
surgical success).
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 69
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
–True sexual abstinence, only  if this is in line with the preferred and usual lifesty le of 
the subject. True abstinence is defined as refraining from hete
rosexual intercourse 
during the entire period of the study , from [ADDRESS_399796] dose.
2.Unacceptable methods of contraception are:
Periodic abstinence (eg, calendar, ovulation, sy mptothermal, post -ovulation methods).
Spermicides only .
Withdrawal.
No method at all.
Use of female and male condoms together.
Cap/diaphragm/sponge without spermicide and without condom.
Hormonal contraception
3.Subjects will be provided with information on highly  effective/effective methods of
contraception as part of the subject informed consent process and will be asked to sign a 
consent form stating that they understand the requirements for avoidance of pregnancy , 
donation of ova, and sperm donation during the course of the stud y.
4.During the course of the study , regular hCG pregnancy  tests will be performed for all women 
and all subjects (male and female) will receive continued guidance with respect to the 
avoidance of pregnancy  and sperm or ova donation as part of the stud y procedures. Such 
guidance should include a reminder of the following:
a)contraceptive requirements of the study
b) reasons for use of barrier methods (i.e., condom) in males with pregnant partners
c)assessment of subject compliance through questions such as
i.Have you used the contraception consistently  and correctly  since the last visit?
ii.Have you forgotten to use contraception since the last visit?
iii.Are your menses late (even in women with irregular or infrequent menstrual cy cles a 
pregnancy  test must be performed if the answer is “yes”)
iv.Is there a chance you could be pregnant ?
5.In addition to a negative serum hCG pregnancy  test at screening, female subjects of 
childbearing potential must also have confirmed menses in the month before first dosing (no 
delay ed menses; with the exception of female subjects using a protocol acceptable 
contraception method that has a known side effect of delay ed or irregular menses), and, a 
negative serum hCG pregnancy  test at each check -in prior to receiving an y dose of study 
medication.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399797] to the Avoidance of Pregnancy
Such guidance should include a reminder of the following:
contraceptive requirements of the study .
reasons for use of barrier methods (i.e., condom) in males with pregnant partners.
assessment of subject c ompliance through questions such as:
–Have you used the contraception consistently and correctly since the last visit?
–
Have you forgotten to use contraception since the last visit? 
–Are your menses late (even in women with irregular or infrequent menstrual cycles a 
pregnancy  test must be performed if the answer is “y es”)
–Is there a chance you could be pregnant ?
Pregnancy
If any subject is found to be pregnant during the study she should be withdrawn and an y 
Sponsor -supplied drug should be immediately  discont inued. I n addition, any  pregnancies in the 
partner of a male subject during the stud y or for [ADDRESS_399798]’s partner. 
If the female subject agrees to the primary  care phy sician being informed, the investigator should 
notify  the primary  care phy sician that the female subject was participating in a clinical study  at 
the time she became pregnant and provide details of the study  drug the subject received.
All pregnancies, including female partners of male subjects will be followed up to final outcome, 
using the pregnancy  form. Pregnancies will remain blinded to the study  team. The outcome, 
including an y premature termination, must be reported to the Sponsor. An evaluation after the 
birth of the child will also be conducted.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 71
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
Appendix E Detailed Description of Amendments to Text
Amendment 1
Change 1. The term bioequivalence has been updated to bioavailability  throughout the 
protocol. 
The change occurs in the protocol title and throughout the study  protocol.
Initial 
wording 
(Title): A Randomized, Open -label, Two-treatment, Two- period, Single -dose, 
Crossover Study  to Evaluate the Bioequivalence of Teduglutide Administered 
Subcutaneously  by [CONTACT_323949] y Adult 
Subjects
Amended 
or new 
wording 
(Title):A Randomized, Open -label, Two-treatment, Two- period, Single -dose, 
Crossover Study  to Evaluate the Bioavailability  of Teduglutide Administered 
Subcutaneously  by [CONTACT_323950] y Adult 
Subjects
Change 2. The anal ysis conclusion for the primary objective has been modified. 
Due to the change from bioequivalence to bioavailability , the wording in the Sy nopsis -
Statistical Methodology  for Pharmacokinetic Endpoints and in Section 11.1.3 (PK Anal ysis) 
has been modified.
Initial 
wording: To claim bioequivalence between test and reference, the 90% CI for the ratio of 
geometric means for PK metrics, AUC 0-tlast, AUC 0-∞, and C max, would be 
contained within the acceptance interval of 80.00 to 125.00%.
Amended 
or new 
wording:To assess bioavailability  between test and reference, the 90% CI for the ratio of 
geometric means for PK metrics, AUC 0-tlast, AUC 0-∞, and Cmaxwill be derived 
and compared (and would be contained within the acceptance interval of 80.00 
to 125.00% if bioequivalent).
Change 3. Hy pothesis verbiage was removed from the study  protocol. 
Hypothesis verbiage has been removed from Section 5.1 (Hy pothesis ).
Initial 
wording: The plasma PK ( AUC 0-tlast, AUC 0-∞, and C max) of teduglutide following single 
SC administration by  [CONTACT_323930] (reference) and pen injector (test) will be 
bioequivalent, ie, the 90% CI  for the ratio of geometric means for PK metrics, 
AUC 0-tlast, AUC 0-∞, and C max, are contained within the acceptance interval of 
80.00 to 125.00%.
Amended 
wording:Hypothesis testing is not relevant for a bioavai lability  study .
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399799] been added to the secondary  endpoints. 
Additional PK parameters for CL /F (apparent total body  clearance) and Vz/F (apparent volume 
of distribution) have been added to the following sections of the protocol: Sy nopsis (Criteria 
for Evaluation and Anal yses), Section 5.3.2 (Secondary  Endpoints), and Section 9.3.1 (PK 
Measurements)
New 
wording:CL/F: Apparent total body  clearance for extravascular administration 
divided by  [CONTACT_323940]/F: Apparent volume of distribution associated with the terminal slope 
following extravascular administration divided by  [CONTACT_323951] 5. Sample size for the study  has been updated.
The sample size for each cohort has been increased from 15 subjects to 16 subjects and the 
number of planned subjects has thus been updated from 60 to 64 subjects. The following 
sections were updated (Synopsis [ Table 1, Planned Number of Subjects, and Sample Size 
Justification], Sec tion6.1 (Stud y Design [ Table 2]), and Section 11.3 (Determination of 
Sample Size).
Initial 
wording: 
WeightbandCohort/
Dose 
levelNo. of 
Subjects SequenceTreatm ent 
Period 1
(Day 1)Washout 
Period
(7 days)Treatm ent 
Period 2
Day 1)
≥40.0 kg -
≤75.0 kgCohort 
1 / 3mgn=15
ABReference
(fixed dose 
by [CONTACT_323914])*→Test
(fixed dose 
by [CONTACT_323935])*>75.0 kg -
≤120.0 kgCohort 
2 / 4mgn=15
≥40.0 kg -
≤75.0 kgCohort 
1 / 3mgn=[ADDRESS_399800]
(fixed dose 
by [CONTACT_323935])*→Reference
(fixed dose 
by [CONTACT_323914])*>75.0 kg -
≤120.0 kgCohort 
2 / 4mgn=15
Amended 
wording:
WeightbandCohort/
Dose 
levelNo. of 
Subjects SequenceTreatm ent 
Period 1
(Day 1)Washout 
Period
(7 days)Treatm ent 
Period 2
Day 1)
≥40.0 kg -
≤75.0 kgCohort 
1 / 3mgn=16
ABReference
(fixed dose 
by [CONTACT_323914])*→Test
(fixed dose 
by [CONTACT_323935])*>75.0 kg -
≤120.0 kgCohort 
2 / 4mgn=16
≥40.0 kg -
≤75.0 kgCohort 
1 / 3mgn=[ADDRESS_399801]
(fixed dose 
by [CONTACT_323935])*→Reference
(fixed dose 
by [CONTACT_323914])*>75.0 kg -
≤120.0 kgCohort 
2 / 4mgn=16
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 73
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
Initial 
wording: The planned total sample size for this study  is 60 randomized subjects
Amended 
wording:The planned total sample size for this study  is 64 randomized subjects
Initial 
wording: The sample size of 26 subjects within each cohort (13 each sequence) would 
yield 86% power for the co- primary  endpoints (AUC 0-tlast,AUC 0-∞, and C max) 
with a 5% ty pe [ADDRESS_399802]/reference of 1.0 in their 
relative bio -availabilities ba sed on the acceptance interval of 80.00 to 125.00% 
and a Coefficient of Variation of 21%.
To account for approximately  10% potential drop outs and/or non- reliable 
concentration time -profiles, 30 subjects per cohort (15 subjects per sequence 
within each coh ort) will be enrolled leading to a total sample size of 60 subjects. 
This sample size was calculated with Nquery .   
Amended 
wording:The overall power for the endpoints (AUC 0-tlast,AUC 0-∞, and C max) with a total 
sample size of 64 subjects will be 92.6% power based on a 5% t ype 1 error and 
a Coefficient of Variation of 21%, assuming a true ratio of test/reference of 1.0 
in their relative bio -availabilities based on the acceptance interval of 80.00 to 
125.00%. The sample size of 28 subjects within each coh ort (14 each sequence) 
was accounted for approximately  10% potential drop -outs and/or non -reliable 
concentration time -profiles to y ield 32 subjects per cohort (16 subjects per 
sequence within each cohort). This sample size was calculated with SAS v9.
Change 6. The minimum number of subjects to complete each cohort has been increased. 
Verbiage in Secti on7.7 (Subj ect Replacement) has been updated to reflect 14 subjects are to 
complete each cohort.
Initial 
wording: Replacement of discontinued or withdrawn subjects due to any  reason will be 
assessed on a case b y case basis to ensure a minimum of 13 subjects (per cohort 
weightband) complete each treatment in the stud y.
Amended 
wording:Replacement of discontinued or withdrawn subjects due to any  reason will be 
assessed on a case b y case basis to ensure a minimum of 14 subjects (per cohort 
weightband) complete each treatment in the stud y.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 74
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
Amendment 2
Change 1. The IB edition number has been removed from the protocol . Due to ongoing 
updates to the IB, the protocol will reference “the current edition” of the IB or “current IB 
edition” 
The change occurs in the following sections:
Section 4.1 - Introduction
Section 4.3 - Benefit/Risk profile
Section 10.1.[ADDRESS_399803] AEs  
Initial 
wording: Investigator’s Brochure (IB Edition 16.0)
Amended 
or new 
wording:The current edition of the I nvestigator’s Brochure (IB) (Section 4.2) or current 
IB edition (Section 4.3 and Section 10.1.2)
Change 2. Verbiage has been added to the pharmacokinetics section of the introduction to 
clarify  study  information source. 
The change occurs in the following section :
Section 4.1 - Introduction 
Initial 
wording: A maximum mean plasma concentration of 49.7 ng/mL was achieved at 
2.64±1.02 hours (t max) and the mean AUC 0-tand AUC 0-infvalues were 201±51.6 
and 204±51.1 ng•hr/mL , respectivel y. Teduglutide was absorbed and rapi[INVESTIGATOR_323908] t½ of 1.21±0.65 hours. The mean plasma 
cleara nce was 14.5±4.09 L/hr and the mean bod y weight normalized plasma 
clearance was 0.0259±0.0672 L/hr/kg.
Amended 
or new 
wording:Following a o ne-time PK sampling conducted at the beginning of the initial 
24-week teduglutide treatment period (0.05 mg/kg SC once daily )in 
Study TED -C14-004, a maximum mean plasma concentration of 49.7 ng/mL  
was achieved at 2.64±1.02 hours (t max) and the mean AUC 0-tand AUC 0-infvalues 
were 201±51.6 and 204±51.1 ng•hr/mL, respectively . Teduglutide was absorbed 
and rapi[INVESTIGATOR_2478] y elimin ated from plasma with mean t½ of 1.21±0.65 hours. The mean 
plasma clearance was 14.5±4.09 L/hr and the mean body  weight normalized 
plasma clearance was 0.0259±0.0672 L/hr/kg.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page [ADDRESS_399804](s) with a positive COVID -[ADDRESS_399805].
Additionally , the exclusion criterion in relation to the safet y 12-lead ECG requirement and the 
inclusion criterion in relation to the age range (updated for Arizona state) has been updated.
The change occurs in the following sections:
Section 1 - Study  Summary
Section 7.2 - Exclusion Criteria
Section 7.1 – Inclusion Criteria
Section 7.2 – Exclusion Criteria (Criterion 3 [new])
Initial 
wording: Not applicable
Amended 
or new 
wording:Positive PCR (poly merase chain reaction) testing for severe acute respi[INVESTIGATOR_323909] -2 (SARS -CoV -2), either with the absence or presence of 
the clinical sy mptoms of COVID -19.
Section 7.2 - Exclusion Criteria ( Criterion 12)
Initial 
wording: Twelve -lead (12) -ECG demonstrating QTcF >470 mse c for females and 
>[ADDRESS_399806]’s eligibility .
Amended 
or new 
wording:Twelve (12) -lead ECG demonstrating QTcF >[ADDRESS_399807]’s eligibility .
Section 7.1 – Inclusion Criteria (Criterion 3)
Initial 
wording: Aged [ADDRESS_399808] screening visit.
Amended 
or new 
wording:Aged [ADDRESS_399809] sc reening visit.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 76
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
Change 4
. Verbiage has been included for the possible extension of confinement due to 
COVID -19 testing.
The change occurs in the following sections:
Section 3 - Schedule of Study  Procedures 
Section 9.3.5 - Confinement
Initial 
wording: Subjects will be admitted to the CRU on Day  -1 of each period at the time 
indicated b y the CRU (Section 3).
Amended 
or new 
wording:Subjects will be admitted to the CRU on Day  -1 of each period at the time 
indicated b y the CRU. Subjects may be admitted earlier for Coronavirus 
Disease -19 (COVID -19) testing not related to study  protocol as per CRU 
requirements. If the CRU decides to confine the subjects throughout the study  
(ie, washout period[s]), some safet y events at check -in (e.g., clinical laboratory  
test, urine drug and alcohol screen, pregnancy  test, and vital signs) may  not be 
performed at the investigator’s discretion.
Amended 
or new 
wording:Subjects may  be admitted earlier for COVID -19 testing not related to study  
protocol as per CRU requirement s. (Section 9.3.5)
Change 5. Two additional conditions related to COVID- [ADDRESS_399810].
The change occurs in the following section:
Section 10.1.1 – SAEs (Table 5) 
Initial 
wording: Not Applicable.
Amended 
or new 
wording:The terms COVID -[ADDRESS_399811] been 
added to Table 5. In addition the following footnote to Table 5 has been added:
“Note: Terms identified on the Medicall y Significant AE L ist represent the 
broad medical concepts to be considered as “I mportant Medical Events” 
satisfy ing SAE reporting requirements.”
Change 6. Verbiage has been updated to allow for the possibility  of remote monitoring due to 
COVID -19.
The change occurs in the following section:
Section 12.1 – Study  Site Monitoring Visits 
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 77
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
Initial 
wording: Monitoring visits to the study  site will be made periodically  during the study  to 
ensure that all aspects of the protocol are followed.
Amended 
or new 
wording:Monitoring visits to the study  site may  be made periodically  during the study  to 
ensure that all aspects of the protocol are followed. Due to COVID -19, 
monitoring visits may  also be conducted remotel y.
Change 7. Verbiage has been added relevant to the recording of protocol deviations 
surrounding COVID -19.
The change occurs in the following section:
Section 12.2 – Protocol Deviations 
Initial 
wording: Not Applicable.
Amended 
or new 
wording:For COVID -19-related protocol deviations, the specific protocol deviation, the 
reason for the deviation, and the relationship to COVID-[ADDRESS_399812] processes.
Change 8. As requested by  [CONTACT_2165], 2 additional injection sites were 
added. Subjects will also be randomized for injection site.
Thechange occurs in the following sections:
Section 1 - Synopsis (Table 1 and exclusion criteria)
Section 3 - Schedule of Study  Procedures 
Section 6.1 - Study  design (Table 2)
Section 6.3.1 - Rationale for Study  Design
Section 7.2 -
Exclusion Criteria
Section 8.1.4 - Randomization Code and Storage
Section 9.2.7 - Study  Drug Administration
Initial 
wording: Not Applicable.
Amended 
or new 
wording:The following verbiage has been added to Section 1, Section 6.3.1, and 
Section 8.1.4: “To ensure adequate d istribution across 3 injection sites (ie, thigh, 
abdomen, and arm), randomization will be stratified by  [CONTACT_323952]” 
Initial 
wording:Will be performed in Period 1 only  (Footnote “g” of Section 3 [Randomization])
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 78
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
Amended 
or new 
wording:Will be performed in Period 1 only . Subjects will be assigned to a cohort based 
on their weight and will receive the study  treatments according to the 
randomization scheme. In each cohort, subjects will be randomized to 1 of 2 
sequences and admini stered a single dose of teduglutide on Day  1 of each period 
per the randomization sequences, either AB or BA (as defined in the study 
protocol. To ensure adequate distribution across 3 injection sites (ie, thigh, 
abdomen, and arm), randomization will also be stratified by [CONTACT_323953].
Initial 
wording:Presence of lesions, rashes, tattoos, and moles etc. on administration sites on the 
abdomen not allowing adequate conduct of injection site reaction and injection 
site injury  (Synopsis a nd Section 7.2)
Amended 
or new 
wording:Presence of lesions, rashes, tattoos, and moles etc. on administration sites not 
allowing adequate conduct of injection site reaction and injection site injury
Initial 
wording:In each period, subjects will receive teduglutide administered SC to the 
abdomen either b y syringe injection (s yringe and vial) or pen injector. A 
different abdominal site will be used for administration in the subsequent period. 
Time of administration and administration site location will be recorded 
(Section 9.2.7)
Amended 
or new 
wording:In each period, subjects will receive teduglutide administered SC to the arm, 
thigh or abdomen either by  [CONTACT_323930] (s yringe and vial) or pen injector. 
The same location (ie, arm, thigh or abdomen) but a different puncture spot will 
be used for administration in the subsequent period. Time of administration and 
administration site location will be recorded.
Change 9. Minor editorial changes have been made throughout the protocol and consistency  
verbiage update sto Appendix B on male/female contracept ion were made to match 
Appendix D.
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 79
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
Amendment 3
Change 1. As requested by  [CONTACT_323954], b
lood sampling for anti- drug 
antibody  anal ysis is not required and has been removed from t he protocol.
The following updates were made:
Section 3 (Schedule of Study  Procedures) – row for immunogenicit y sampling has been 
removed.
Section 9.3 (PK Samples) -Table 4 for Primary  Specimen Collections, row for 
immunogenicit y sample has been removed.
Section 9.3.4 (I mmunogen icity) has been removed.
Change 2. As requested by  [CONTACT_323954], PK analy sis is also required to 
be evaluated b y injection site.
The following secondary objective was added to the Sy nopsis and Section 5.2.2 (Study  
Secondary  Objectives):
To evaluate the bioavailability  of teduglutide, by  [CONTACT_93403] (ie, thigh, abdomen, and arm) , 
following the administration of a single, SC fixed dose of 3 mg or 4 mg teduglutide 
(depending upon subjects assignment in one of two cohorts as defined by  [CONTACT_18559]) 
administered via manual injection or via pe n injector in healthy  subjects.
The following PK endpoints were added to the Synopsis and Section 5.3.2 (Secondary  
Endpoints)
PK metrics* by  [CONTACT_93403] ( ie, thigh, abdo men, and arm) including:
AUC 0-tlast: Area under the concentration curve from time zero to the time of last 
measurable concentration 
Cmax: Maximum concentration
AUC 0-∞: Area under the concentration curve extrapolated to infinite time
*Beginning on Day  1 of each period, PK parameters will be calculated from reliable 
teduglutide concentration- time profiles using non -
compartmental methods where all 
calculations will be based on actual sampling times.
The following sentence was added to the S ynopsis (Statistical Considerations) and to 
Section 11.1.3 (PK Analy sis)(Third Paragraph) :
“The PKendpoints will also be anal yzed by [CONTACT_93403] (ie, thigh, abdomen, and arm) ”
For non-commercial use only
[COMPANY_005] CONFIDENTIAL Page 80
TAK -633-1001 Protocol Amendment 03
Teduglutide 09 Dec 2020
Change 3. 
An error in the lower age range was corrected.
The c orrection occur redinthe following section:
Section 1 (Study  Summary ) –Study  Subject Population (First Sentence)
Initial 
wording: Health y male and female subjects aged 1 9 –45 yearsinclusive, at time of 
consent.
Amended 
or new 
wording:Health y male and female subjects aged 18 –45 yearsinclusive, at time of 
consent.
For non-commercial use only